date generated: 2022-05-07
Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch
Here is the first few lines of the input profile.
## metric
## PSMB8 -7.305627
## PPT2 -5.941684
## PSMB9 -8.456132
## PEG10 -6.426739
## SGCE -6.469123
## KIAA1949 -5.842438
Here are some metrics about the input data profile:
Profile metrics | |
---|---|
num_genesets | 2546 |
num_genes_in_profile | 9840 |
duplicated_genes_present | 0 |
num_profile_genes_in_sets | 5255 |
num_profile_genes_not_in_sets | 4585 |
Here is a plot of the input profiles. Note the dynamic ranges.
Here is the contour plot of the profile including all detected genes.
Gene sets metrics | |
---|---|
num_genesets | 2546 |
num_genesets_excluded | 1377 |
num_genesets_included | 1169 |
Significance is calculated by -log10(p-value). All points shown are FDR<0.05.
Significance is calculated by -log10(p-value). Top N sets shown irrespective of FDR.
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Purine catabolism | 10 | 0.009170 | -0.476 | 0.1580 |
Meiotic recombination | 19 | 0.000838 | -0.443 | 0.0515 |
p75NTR signals via NF-kB | 11 | 0.011800 | -0.439 | 0.1640 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 11 | 0.012600 | 0.435 | 0.1730 |
Signaling by Leptin | 10 | 0.018200 | 0.431 | 0.2090 |
Signaling by BMP | 14 | 0.005530 | 0.428 | 0.1300 |
IKK complex recruitment mediated by RIP1 | 17 | 0.006630 | -0.380 | 0.1380 |
Ras activation upon Ca2+ influx through NMDA receptor | 10 | 0.039600 | 0.376 | 0.2790 |
Potassium Channels | 23 | 0.001890 | 0.374 | 0.0919 |
SARS-CoV-2 modulates autophagy | 10 | 0.046700 | -0.363 | 0.3130 |
tRNA Aminoacylation | 22 | 0.003210 | -0.363 | 0.1170 |
Processing of Intronless Pre-mRNAs | 15 | 0.015300 | -0.362 | 0.1970 |
Mitochondrial tRNA aminoacylation | 17 | 0.010200 | -0.360 | 0.1600 |
Mucopolysaccharidoses | 10 | 0.053200 | 0.353 | 0.3310 |
HDMs demethylate histones | 15 | 0.019900 | -0.347 | 0.2190 |
Collagen degradation | 10 | 0.059400 | 0.344 | 0.3420 |
Erythropoietin activates RAS | 10 | 0.059400 | 0.344 | 0.3420 |
Interleukin-20 family signaling | 13 | 0.036200 | 0.336 | 0.2720 |
RIPK1-mediated regulated necrosis | 24 | 0.004580 | -0.334 | 0.1170 |
Regulation of necroptotic cell death | 24 | 0.004580 | -0.334 | 0.1170 |
Activation of G protein gated Potassium channels | 10 | 0.070900 | 0.330 | 0.3610 |
G protein gated Potassium channels | 10 | 0.070900 | 0.330 | 0.3610 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 10 | 0.070900 | 0.330 | 0.3610 |
Caspase activation via Death Receptors in the presence of ligand | 10 | 0.071100 | -0.330 | 0.3610 |
Activation of kainate receptors upon glutamate binding | 15 | 0.027200 | 0.329 | 0.2480 |
Signaling by Erythropoietin | 18 | 0.015800 | 0.329 | 0.1970 |
Translesion Synthesis by POLH | 16 | 0.023500 | -0.327 | 0.2290 |
Impaired BRCA2 binding to RAD51 | 30 | 0.001960 | -0.327 | 0.0919 |
Mitochondrial calcium ion transport | 14 | 0.034700 | 0.326 | 0.2680 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 0.035800 | -0.324 | 0.2720 |
Interleukin-10 signaling | 12 | 0.052100 | 0.324 | 0.3270 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 15 | 0.030800 | -0.322 | 0.2610 |
Chaperone Mediated Autophagy | 12 | 0.054400 | -0.321 | 0.3360 |
Downregulation of ERBB2 signaling | 17 | 0.022200 | -0.320 | 0.2230 |
TICAM1, RIP1-mediated IKK complex recruitment | 17 | 0.022500 | -0.320 | 0.2230 |
RHO GTPases activate CIT | 14 | 0.038700 | -0.319 | 0.2760 |
Glycogen synthesis | 11 | 0.066900 | -0.319 | 0.3600 |
Signaling by WNT in cancer | 22 | 0.010400 | 0.316 | 0.1600 |
Cytosolic sulfonation of small molecules | 10 | 0.084700 | 0.315 | 0.3900 |
Negative regulation of FLT3 | 10 | 0.084800 | -0.315 | 0.3900 |
Cell-cell junction organization | 12 | 0.059300 | 0.315 | 0.3420 |
Generation of second messenger molecules | 12 | 0.060600 | 0.313 | 0.3430 |
Meiosis | 39 | 0.000785 | -0.311 | 0.0510 |
Prostacyclin signalling through prostacyclin receptor | 10 | 0.089200 | 0.310 | 0.3940 |
Assembly and cell surface presentation of NMDA receptors | 12 | 0.063700 | 0.309 | 0.3500 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 24 | 0.009010 | -0.308 | 0.1580 |
mRNA 3’-end processing | 30 | 0.004180 | -0.302 | 0.1170 |
Long-term potentiation | 10 | 0.098900 | 0.301 | 0.4100 |
Myogenesis | 13 | 0.061000 | -0.300 | 0.3430 |
Presynaptic phase of homologous DNA pairing and strand exchange | 32 | 0.003670 | -0.297 | 0.1170 |
set | setSize | pANOVA | s.dist | p.adjustANOVA |
---|---|---|---|---|
Purine catabolism | 10 | 9.17e-03 | -0.476000 | 0.158000 |
Meiotic recombination | 19 | 8.38e-04 | -0.443000 | 0.051500 |
p75NTR signals via NF-kB | 11 | 1.18e-02 | -0.439000 | 0.164000 |
Negative regulation of NMDA receptor-mediated neuronal transmission | 11 | 1.26e-02 | 0.435000 | 0.173000 |
Signaling by Leptin | 10 | 1.82e-02 | 0.431000 | 0.209000 |
Signaling by BMP | 14 | 5.53e-03 | 0.428000 | 0.130000 |
IKK complex recruitment mediated by RIP1 | 17 | 6.63e-03 | -0.380000 | 0.138000 |
Ras activation upon Ca2+ influx through NMDA receptor | 10 | 3.96e-02 | 0.376000 | 0.279000 |
Potassium Channels | 23 | 1.89e-03 | 0.374000 | 0.091900 |
SARS-CoV-2 modulates autophagy | 10 | 4.67e-02 | -0.363000 | 0.313000 |
tRNA Aminoacylation | 22 | 3.21e-03 | -0.363000 | 0.117000 |
Processing of Intronless Pre-mRNAs | 15 | 1.53e-02 | -0.362000 | 0.197000 |
Mitochondrial tRNA aminoacylation | 17 | 1.02e-02 | -0.360000 | 0.160000 |
Mucopolysaccharidoses | 10 | 5.32e-02 | 0.353000 | 0.331000 |
HDMs demethylate histones | 15 | 1.99e-02 | -0.347000 | 0.219000 |
Collagen degradation | 10 | 5.94e-02 | 0.344000 | 0.342000 |
Erythropoietin activates RAS | 10 | 5.94e-02 | 0.344000 | 0.342000 |
Interleukin-20 family signaling | 13 | 3.62e-02 | 0.336000 | 0.272000 |
RIPK1-mediated regulated necrosis | 24 | 4.58e-03 | -0.334000 | 0.117000 |
Regulation of necroptotic cell death | 24 | 4.58e-03 | -0.334000 | 0.117000 |
Activation of G protein gated Potassium channels | 10 | 7.09e-02 | 0.330000 | 0.361000 |
G protein gated Potassium channels | 10 | 7.09e-02 | 0.330000 | 0.361000 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | 10 | 7.09e-02 | 0.330000 | 0.361000 |
Caspase activation via Death Receptors in the presence of ligand | 10 | 7.11e-02 | -0.330000 | 0.361000 |
Activation of kainate receptors upon glutamate binding | 15 | 2.72e-02 | 0.329000 | 0.248000 |
Signaling by Erythropoietin | 18 | 1.58e-02 | 0.329000 | 0.197000 |
Translesion Synthesis by POLH | 16 | 2.35e-02 | -0.327000 | 0.229000 |
Impaired BRCA2 binding to RAD51 | 30 | 1.96e-03 | -0.327000 | 0.091900 |
Mitochondrial calcium ion transport | 14 | 3.47e-02 | 0.326000 | 0.268000 |
Golgi Cisternae Pericentriolar Stack Reorganization | 14 | 3.58e-02 | -0.324000 | 0.272000 |
Interleukin-10 signaling | 12 | 5.21e-02 | 0.324000 | 0.327000 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | 15 | 3.08e-02 | -0.322000 | 0.261000 |
Chaperone Mediated Autophagy | 12 | 5.44e-02 | -0.321000 | 0.336000 |
Downregulation of ERBB2 signaling | 17 | 2.22e-02 | -0.320000 | 0.223000 |
TICAM1, RIP1-mediated IKK complex recruitment | 17 | 2.25e-02 | -0.320000 | 0.223000 |
RHO GTPases activate CIT | 14 | 3.87e-02 | -0.319000 | 0.276000 |
Glycogen synthesis | 11 | 6.69e-02 | -0.319000 | 0.360000 |
Signaling by WNT in cancer | 22 | 1.04e-02 | 0.316000 | 0.160000 |
Cytosolic sulfonation of small molecules | 10 | 8.47e-02 | 0.315000 | 0.390000 |
Negative regulation of FLT3 | 10 | 8.48e-02 | -0.315000 | 0.390000 |
Cell-cell junction organization | 12 | 5.93e-02 | 0.315000 | 0.342000 |
Generation of second messenger molecules | 12 | 6.06e-02 | 0.313000 | 0.343000 |
Meiosis | 39 | 7.85e-04 | -0.311000 | 0.051000 |
Prostacyclin signalling through prostacyclin receptor | 10 | 8.92e-02 | 0.310000 | 0.394000 |
Assembly and cell surface presentation of NMDA receptors | 12 | 6.37e-02 | 0.309000 | 0.350000 |
Resolution of D-loop Structures through Holliday Junction Intermediates | 24 | 9.01e-03 | -0.308000 | 0.158000 |
mRNA 3’-end processing | 30 | 4.18e-03 | -0.302000 | 0.117000 |
Long-term potentiation | 10 | 9.89e-02 | 0.301000 | 0.410000 |
Myogenesis | 13 | 6.10e-02 | -0.300000 | 0.343000 |
Presynaptic phase of homologous DNA pairing and strand exchange | 32 | 3.67e-03 | -0.297000 | 0.117000 |
Resolution of D-Loop Structures | 25 | 1.05e-02 | -0.296000 | 0.160000 |
FOXO-mediated transcription of cell death genes | 14 | 5.65e-02 | 0.294000 | 0.338000 |
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | 21 | 2.09e-02 | -0.291000 | 0.219000 |
Miscellaneous transport and binding events | 13 | 6.90e-02 | -0.291000 | 0.361000 |
Processing of Capped Intronless Pre-mRNA | 23 | 1.58e-02 | -0.291000 | 0.197000 |
Inwardly rectifying K+ channels | 11 | 1.00e-01 | 0.286000 | 0.413000 |
Class B/2 (Secretin family receptors) | 26 | 1.15e-02 | 0.286000 | 0.163000 |
Leading Strand Synthesis | 12 | 8.86e-02 | -0.284000 | 0.394000 |
Polymerase switching | 12 | 8.86e-02 | -0.284000 | 0.394000 |
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function | 19 | 3.36e-02 | -0.282000 | 0.264000 |
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function | 19 | 3.36e-02 | -0.282000 | 0.264000 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | 19 | 3.36e-02 | -0.282000 | 0.264000 |
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | 19 | 3.36e-02 | -0.282000 | 0.264000 |
Impaired BRCA2 binding to PALB2 | 19 | 3.36e-02 | -0.282000 | 0.264000 |
Cell junction organization | 21 | 2.56e-02 | 0.281000 | 0.241000 |
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 25 | 1.51e-02 | -0.281000 | 0.197000 |
HDR through Homologous Recombination (HRR) | 55 | 3.38e-04 | -0.280000 | 0.029600 |
LDL clearance | 11 | 1.09e-01 | -0.279000 | 0.428000 |
Defective homologous recombination repair (HRR) due to BRCA2 loss of function | 33 | 5.66e-03 | -0.278000 | 0.130000 |
Diseases of DNA Double-Strand Break Repair | 33 | 5.66e-03 | -0.278000 | 0.130000 |
Pexophagy | 11 | 1.12e-01 | -0.277000 | 0.434000 |
HDR through Single Strand Annealing (SSA) | 33 | 6.23e-03 | -0.275000 | 0.133000 |
Homologous DNA Pairing and Strand Exchange | 35 | 4.97e-03 | -0.275000 | 0.124000 |
Caspase activation via extrinsic apoptotic signalling pathway | 15 | 6.64e-02 | -0.274000 | 0.360000 |
A tetrasaccharide linker sequence is required for GAG synthesis | 10 | 1.35e-01 | 0.273000 | 0.463000 |
Removal of the Flap Intermediate | 12 | 1.02e-01 | -0.273000 | 0.418000 |
RNA Polymerase II Transcription Termination | 38 | 3.72e-03 | -0.272000 | 0.117000 |
Condensation of Prophase Chromosomes | 12 | 1.03e-01 | -0.272000 | 0.418000 |
GPCR ligand binding | 68 | 1.15e-04 | 0.271000 | 0.019200 |
Removal of the Flap Intermediate from the C-strand | 15 | 7.46e-02 | -0.266000 | 0.368000 |
Synthesis of very long-chain fatty acyl-CoAs | 10 | 1.50e-01 | 0.263000 | 0.485000 |
EGFR downregulation | 20 | 4.36e-02 | -0.261000 | 0.303000 |
Deposition of new CENPA-containing nucleosomes at the centromere | 20 | 4.40e-02 | -0.260000 | 0.303000 |
Nucleosome assembly | 20 | 4.40e-02 | -0.260000 | 0.303000 |
CD209 (DC-SIGN) signaling | 15 | 8.12e-02 | 0.260000 | 0.384000 |
Gap-filling DNA repair synthesis and ligation in GG-NER | 23 | 3.10e-02 | -0.260000 | 0.261000 |
Collagen formation | 18 | 5.70e-02 | 0.259000 | 0.338000 |
Stabilization of p53 | 46 | 2.48e-03 | -0.258000 | 0.103000 |
RUNX2 regulates osteoblast differentiation | 12 | 1.23e-01 | 0.258000 | 0.448000 |
Citric acid cycle (TCA cycle) | 18 | 5.92e-02 | -0.257000 | 0.342000 |
Rap1 signalling | 11 | 1.40e-01 | -0.257000 | 0.474000 |
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | 15 | 8.69e-02 | -0.255000 | 0.394000 |
Nucleotide catabolism | 20 | 4.85e-02 | -0.255000 | 0.321000 |
Translesion synthesis by POLK | 15 | 8.80e-02 | -0.255000 | 0.394000 |
Regulation of IFNG signaling | 12 | 1.28e-01 | 0.254000 | 0.452000 |
VxPx cargo-targeting to cilium | 16 | 7.87e-02 | 0.254000 | 0.380000 |
Recognition of DNA damage by PCNA-containing replication complex | 26 | 2.55e-02 | -0.253000 | 0.241000 |
SARS-CoV-2 modulates host translation machinery | 38 | 7.44e-03 | -0.251000 | 0.141000 |
RAC3 GTPase cycle | 54 | 1.44e-03 | 0.251000 | 0.076300 |
Reproduction | 43 | 4.45e-03 | -0.251000 | 0.117000 |
Defects in vitamin and cofactor metabolism | 16 | 8.33e-02 | -0.250000 | 0.386000 |
STING mediated induction of host immune responses | 10 | 1.71e-01 | 0.250000 | 0.516000 |
Processing of DNA double-strand break ends | 51 | 2.15e-03 | -0.249000 | 0.093200 |
DARPP-32 events | 18 | 6.84e-02 | 0.248000 | 0.361000 |
Regulation of TP53 Activity through Phosphorylation | 74 | 2.41e-04 | -0.247000 | 0.024200 |
Plasma lipoprotein clearance | 21 | 5.03e-02 | -0.247000 | 0.321000 |
Regulation of TP53 Activity through Methylation | 16 | 8.76e-02 | -0.247000 | 0.394000 |
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | 14 | 1.12e-01 | 0.245000 | 0.434000 |
AKT phosphorylates targets in the cytosol | 13 | 1.26e-01 | -0.245000 | 0.452000 |
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 77 | 2.29e-04 | -0.243000 | 0.024200 |
Molecules associated with elastic fibres | 10 | 1.84e-01 | -0.243000 | 0.530000 |
VLDLR internalisation and degradation | 11 | 1.64e-01 | -0.242000 | 0.513000 |
Detoxification of Reactive Oxygen Species | 22 | 4.99e-02 | 0.242000 | 0.321000 |
Hh mutants are degraded by ERAD | 44 | 6.09e-03 | -0.239000 | 0.133000 |
Hedgehog ligand biogenesis | 48 | 4.21e-03 | -0.239000 | 0.117000 |
Homology Directed Repair | 83 | 1.84e-04 | -0.238000 | 0.023900 |
Hh mutants abrogate ligand secretion | 45 | 5.91e-03 | -0.237000 | 0.133000 |
Integrin signaling | 14 | 1.24e-01 | -0.237000 | 0.450000 |
Platelet Aggregation (Plug Formation) | 14 | 1.24e-01 | -0.237000 | 0.450000 |
Autodegradation of the E3 ubiquitin ligase COP1 | 41 | 8.68e-03 | -0.237000 | 0.156000 |
N-Glycan antennae elongation | 11 | 1.75e-01 | 0.236000 | 0.519000 |
Negative regulation of FGFR1 signaling | 17 | 9.27e-02 | -0.236000 | 0.394000 |
Negative regulation of FGFR2 signaling | 17 | 9.27e-02 | -0.236000 | 0.394000 |
Negative regulation of FGFR3 signaling | 17 | 9.27e-02 | -0.236000 | 0.394000 |
Negative regulation of FGFR4 signaling | 17 | 9.27e-02 | -0.236000 | 0.394000 |
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | 10 | 1.98e-01 | -0.235000 | 0.537000 |
alpha-linolenic acid (ALA) metabolism | 10 | 1.98e-01 | -0.235000 | 0.537000 |
G2/M DNA damage checkpoint | 51 | 3.98e-03 | -0.233000 | 0.117000 |
ER-Phagosome pathway | 63 | 1.50e-03 | -0.232000 | 0.076500 |
Class A/1 (Rhodopsin-like receptors) | 40 | 1.14e-02 | 0.232000 | 0.162000 |
Cobalamin (Cbl, vitamin B12) transport and metabolism | 10 | 2.06e-01 | -0.231000 | 0.548000 |
mRNA decay by 3’ to 5’ exoribonuclease | 14 | 1.38e-01 | -0.229000 | 0.470000 |
Synthesis of PA | 15 | 1.25e-01 | 0.229000 | 0.452000 |
Processive synthesis on the C-strand of the telomere | 17 | 1.04e-01 | -0.228000 | 0.421000 |
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon | 13 | 1.57e-01 | -0.227000 | 0.496000 |
Nucleotide biosynthesis | 12 | 1.75e-01 | 0.226000 | 0.519000 |
NOD1/2 Signaling Pathway | 22 | 6.72e-02 | -0.226000 | 0.360000 |
Regulation of pyruvate dehydrogenase (PDH) complex | 10 | 2.18e-01 | 0.225000 | 0.553000 |
Signaling by KIT in disease | 16 | 1.20e-01 | 0.225000 | 0.444000 |
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | 16 | 1.20e-01 | 0.225000 | 0.444000 |
Regulation of TP53 Degradation | 33 | 2.61e-02 | -0.224000 | 0.241000 |
Regulation of TP53 Expression and Degradation | 33 | 2.61e-02 | -0.224000 | 0.241000 |
Lagging Strand Synthesis | 17 | 1.10e-01 | -0.224000 | 0.431000 |
Phase I - Functionalization of compounds | 29 | 3.74e-02 | 0.223000 | 0.275000 |
Antigen Presentation: Folding, assembly and peptide loading of class I MHC | 23 | 6.55e-02 | -0.222000 | 0.356000 |
RIP-mediated NFkB activation via ZBP1 | 13 | 1.67e-01 | -0.222000 | 0.514000 |
Diseases associated with O-glycosylation of proteins | 17 | 1.14e-01 | 0.221000 | 0.434000 |
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | 31 | 3.31e-02 | 0.221000 | 0.264000 |
Translesion synthesis by REV1 | 14 | 1.53e-01 | -0.221000 | 0.489000 |
Cardiac conduction | 40 | 1.61e-02 | 0.220000 | 0.198000 |
Defective CFTR causes cystic fibrosis | 49 | 7.90e-03 | -0.220000 | 0.144000 |
Regulation of FZD by ubiquitination | 12 | 1.92e-01 | 0.218000 | 0.534000 |
Formation of the ternary complex, and subsequently, the 43S complex | 39 | 1.91e-02 | -0.217000 | 0.215000 |
HDR through MMEJ (alt-NHEJ) | 11 | 2.15e-01 | -0.216000 | 0.551000 |
Glucagon-type ligand receptors | 12 | 1.96e-01 | 0.216000 | 0.537000 |
G beta:gamma signalling through PLC beta | 11 | 2.16e-01 | 0.216000 | 0.551000 |
Presynaptic function of Kainate receptors | 11 | 2.16e-01 | 0.216000 | 0.551000 |
COPII-mediated vesicle transport | 47 | 1.08e-02 | -0.215000 | 0.160000 |
ER Quality Control Compartment (ERQC) | 18 | 1.16e-01 | -0.214000 | 0.437000 |
Hyaluronan metabolism | 10 | 2.41e-01 | -0.214000 | 0.579000 |
Diseases of DNA repair | 41 | 1.80e-02 | -0.214000 | 0.209000 |
p53-Dependent G1 DNA Damage Response | 53 | 7.56e-03 | -0.212000 | 0.141000 |
p53-Dependent G1/S DNA damage checkpoint | 53 | 7.56e-03 | -0.212000 | 0.141000 |
PCNA-Dependent Long Patch Base Excision Repair | 18 | 1.20e-01 | -0.212000 | 0.444000 |
Vif-mediated degradation of APOBEC3G | 40 | 2.09e-02 | -0.211000 | 0.219000 |
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | 33 | 3.67e-02 | -0.210000 | 0.273000 |
Peptide ligand-binding receptors | 17 | 1.34e-01 | 0.210000 | 0.461000 |
Neurotransmitter release cycle | 17 | 1.34e-01 | 0.210000 | 0.461000 |
DNA Double-Strand Break Repair | 108 | 1.70e-04 | -0.210000 | 0.023900 |
ZBP1(DAI) mediated induction of type I IFNs | 16 | 1.46e-01 | -0.210000 | 0.478000 |
Sensory processing of sound | 23 | 8.21e-02 | 0.210000 | 0.384000 |
Sensory processing of sound by inner hair cells of the cochlea | 23 | 8.21e-02 | 0.210000 | 0.384000 |
mRNA Splicing - Major Pathway | 130 | 4.07e-05 | -0.209000 | 0.011900 |
Spry regulation of FGF signaling | 15 | 1.62e-01 | -0.209000 | 0.508000 |
Chondroitin sulfate/dermatan sulfate metabolism | 24 | 7.70e-02 | 0.209000 | 0.378000 |
ABC transporter disorders | 55 | 7.59e-03 | -0.208000 | 0.141000 |
G alpha (i) signalling events | 81 | 1.25e-03 | 0.208000 | 0.069500 |
Signaling by PDGFR in disease | 15 | 1.64e-01 | 0.208000 | 0.513000 |
Carboxyterminal post-translational modifications of tubulin | 19 | 1.18e-01 | 0.207000 | 0.443000 |
Meiotic synapsis | 22 | 9.30e-02 | -0.207000 | 0.394000 |
G beta:gamma signalling through CDC42 | 11 | 2.39e-01 | 0.205000 | 0.579000 |
Purine salvage | 10 | 2.64e-01 | -0.204000 | 0.600000 |
Activation of NMDA receptors and postsynaptic events | 42 | 2.23e-02 | 0.204000 | 0.223000 |
Downregulation of ERBB2:ERBB3 signaling | 10 | 2.65e-01 | -0.204000 | 0.600000 |
Translation initiation complex formation | 45 | 1.82e-02 | -0.204000 | 0.209000 |
Ephrin signaling | 11 | 2.46e-01 | 0.202000 | 0.582000 |
PKMTs methylate histone lysines | 23 | 9.41e-02 | 0.202000 | 0.397000 |
DNA Damage Bypass | 40 | 2.75e-02 | -0.202000 | 0.249000 |
Signaling by Retinoic Acid | 17 | 1.51e-01 | 0.201000 | 0.486000 |
Telomere Extension By Telomerase | 18 | 1.43e-01 | -0.200000 | 0.474000 |
RAC2 GTPase cycle | 52 | 1.29e-02 | 0.199000 | 0.176000 |
Nicotinamide salvaging | 10 | 2.75e-01 | 0.199000 | 0.614000 |
Aggrephagy | 19 | 1.33e-01 | -0.199000 | 0.461000 |
AUF1 (hnRNP D0) binds and destabilizes mRNA | 43 | 2.50e-02 | -0.198000 | 0.239000 |
Ubiquitin-dependent degradation of Cyclin D | 41 | 2.86e-02 | -0.198000 | 0.257000 |
Constitutive Signaling by AKT1 E17K in Cancer | 23 | 1.01e-01 | -0.198000 | 0.415000 |
Resolution of AP sites via the multiple-nucleotide patch replacement pathway | 20 | 1.28e-01 | -0.197000 | 0.452000 |
Disorders of Developmental Biology | 10 | 2.84e-01 | 0.196000 | 0.614000 |
Disorders of Nervous System Development | 10 | 2.84e-01 | 0.196000 | 0.614000 |
Loss of function of MECP2 in Rett syndrome | 10 | 2.84e-01 | 0.196000 | 0.614000 |
Pervasive developmental disorders | 10 | 2.84e-01 | 0.196000 | 0.614000 |
Signaling by Hippo | 10 | 2.85e-01 | 0.195000 | 0.614000 |
Regulation of mRNA stability by proteins that bind AU-rich elements | 72 | 4.22e-03 | -0.195000 | 0.117000 |
RORA activates gene expression | 11 | 2.62e-01 | 0.195000 | 0.599000 |
Degradation of cysteine and homocysteine | 10 | 2.89e-01 | -0.194000 | 0.614000 |
TRAF3-dependent IRF activation pathway | 14 | 2.11e-01 | 0.193000 | 0.551000 |
Interleukin-35 Signalling | 11 | 2.68e-01 | 0.193000 | 0.605000 |
Ion homeostasis | 25 | 9.52e-02 | 0.193000 | 0.400000 |
HSF1 activation | 21 | 1.27e-01 | -0.192000 | 0.452000 |
Signaling by cytosolic FGFR1 fusion mutants | 16 | 1.84e-01 | 0.192000 | 0.530000 |
Processing of Capped Intron-Containing Pre-mRNA | 177 | 1.21e-05 | -0.192000 | 0.004710 |
Neurexins and neuroligins | 20 | 1.38e-01 | 0.191000 | 0.470000 |
Regulation of activated PAK-2p34 by proteasome mediated degradation | 39 | 3.87e-02 | -0.191000 | 0.276000 |
mRNA Splicing | 138 | 1.12e-04 | -0.191000 | 0.019200 |
Cleavage of the damaged pyrimidine | 14 | 2.16e-01 | -0.191000 | 0.551000 |
Depyrimidination | 14 | 2.16e-01 | -0.191000 | 0.551000 |
Recognition and association of DNA glycosylase with site containing an affected pyrimidine | 14 | 2.16e-01 | -0.191000 | 0.551000 |
SUMOylation of immune response proteins | 10 | 2.96e-01 | 0.191000 | 0.616000 |
ROS and RNS production in phagocytes | 22 | 1.21e-01 | 0.191000 | 0.445000 |
Transport of Mature mRNA Derived from an Intronless Transcript | 37 | 4.53e-02 | -0.190000 | 0.308000 |
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 16 | 1.88e-01 | 0.190000 | 0.531000 |
Post NMDA receptor activation events | 36 | 4.88e-02 | 0.190000 | 0.321000 |
Resolution of Sister Chromatid Cohesion | 88 | 2.14e-03 | -0.190000 | 0.093200 |
The role of GTSE1 in G2/M progression after G2 checkpoint | 49 | 2.17e-02 | -0.190000 | 0.223000 |
Resolution of Abasic Sites (AP sites) | 32 | 6.35e-02 | -0.190000 | 0.350000 |
RUNX2 regulates bone development | 16 | 1.90e-01 | 0.189000 | 0.534000 |
Purine ribonucleoside monophosphate biosynthesis | 10 | 3.00e-01 | 0.189000 | 0.619000 |
Processive synthesis on the lagging strand | 13 | 2.40e-01 | -0.188000 | 0.579000 |
Termination of translesion DNA synthesis | 27 | 9.09e-02 | -0.188000 | 0.394000 |
Sensory processing of sound by outer hair cells of the cochlea | 14 | 2.24e-01 | 0.188000 | 0.558000 |
Regulation of HSF1-mediated heat shock response | 63 | 1.01e-02 | -0.188000 | 0.160000 |
NRIF signals cell death from the nucleus | 13 | 2.44e-01 | -0.187000 | 0.582000 |
DNA Double Strand Break Response | 34 | 6.13e-02 | -0.186000 | 0.343000 |
Signaling by NODAL | 11 | 2.88e-01 | 0.185000 | 0.614000 |
Ion transport by P-type ATPases | 27 | 9.67e-02 | 0.185000 | 0.404000 |
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | 46 | 3.04e-02 | -0.185000 | 0.261000 |
Chromosome Maintenance | 71 | 7.28e-03 | -0.185000 | 0.141000 |
Methylation | 10 | 3.13e-01 | -0.184000 | 0.630000 |
Transport of Mature Transcript to Cytoplasm | 55 | 1.86e-02 | -0.184000 | 0.211000 |
COPI-mediated anterograde transport | 65 | 1.06e-02 | -0.184000 | 0.160000 |
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | 12 | 2.71e-01 | -0.183000 | 0.610000 |
Antigen processing-Cross presentation | 68 | 9.16e-03 | -0.183000 | 0.158000 |
KSRP (KHSRP) binds and destabilizes mRNA | 15 | 2.21e-01 | -0.183000 | 0.557000 |
Attenuation phase | 19 | 1.69e-01 | -0.182000 | 0.514000 |
Inhibition of DNA recombination at telomere | 18 | 1.81e-01 | -0.182000 | 0.526000 |
Regulation of ornithine decarboxylase (ODC) | 40 | 4.66e-02 | -0.182000 | 0.313000 |
G1/S DNA Damage Checkpoints | 55 | 2.02e-02 | -0.181000 | 0.219000 |
BBSome-mediated cargo-targeting to cilium | 16 | 2.15e-01 | -0.179000 | 0.551000 |
Ribosomal scanning and start codon recognition | 45 | 3.78e-02 | -0.179000 | 0.276000 |
GABA receptor activation | 16 | 2.17e-01 | 0.178000 | 0.553000 |
MicroRNA (miRNA) biogenesis | 18 | 1.92e-01 | -0.178000 | 0.534000 |
Platelet homeostasis | 44 | 4.19e-02 | 0.177000 | 0.293000 |
TBC/RABGAPs | 39 | 5.56e-02 | -0.177000 | 0.337000 |
Other interleukin signaling | 12 | 2.89e-01 | 0.177000 | 0.614000 |
Neurotransmitter receptors and postsynaptic signal transmission | 72 | 9.58e-03 | 0.177000 | 0.160000 |
Glutamate Neurotransmitter Release Cycle | 10 | 3.33e-01 | 0.177000 | 0.645000 |
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 16 | 2.22e-01 | -0.176000 | 0.557000 |
Transport of Mature mRNAs Derived from Intronless Transcripts | 38 | 6.03e-02 | -0.176000 | 0.343000 |
Regulation of RUNX1 Expression and Activity | 14 | 2.55e-01 | -0.176000 | 0.589000 |
Pyruvate metabolism | 18 | 1.97e-01 | 0.176000 | 0.537000 |
RUNX3 regulates p14-ARF | 10 | 3.40e-01 | -0.174000 | 0.649000 |
InlB-mediated entry of Listeria monocytogenes into host cell | 11 | 3.18e-01 | -0.174000 | 0.637000 |
Diseases associated with N-glycosylation of proteins | 18 | 2.03e-01 | -0.173000 | 0.543000 |
Netrin-1 signaling | 24 | 1.43e-01 | 0.173000 | 0.474000 |
Vitamin B5 (pantothenate) metabolism | 11 | 3.25e-01 | -0.171000 | 0.643000 |
PRC2 methylates histones and DNA | 11 | 3.26e-01 | -0.171000 | 0.644000 |
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | 33 | 8.96e-02 | -0.171000 | 0.394000 |
Mitotic Prometaphase | 147 | 3.83e-04 | -0.170000 | 0.029800 |
RHO GTPases Activate Formins | 97 | 3.84e-03 | -0.170000 | 0.117000 |
Glycogen metabolism | 17 | 2.25e-01 | -0.170000 | 0.560000 |
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | 12 | 3.08e-01 | -0.170000 | 0.630000 |
Transmission across Chemical Synapses | 91 | 5.31e-03 | 0.169000 | 0.129000 |
ADP signalling through P2Y purinoceptor 12 | 11 | 3.31e-01 | 0.169000 | 0.645000 |
Separation of Sister Chromatids | 136 | 7.02e-04 | -0.169000 | 0.048300 |
Neuronal System | 124 | 1.22e-03 | 0.169000 | 0.069500 |
Downregulation of TGF-beta receptor signaling | 25 | 1.44e-01 | 0.169000 | 0.477000 |
G2/M Checkpoints | 106 | 2.77e-03 | -0.169000 | 0.112000 |
activated TAK1 mediates p38 MAPK activation | 12 | 3.12e-01 | -0.168000 | 0.630000 |
Base Excision Repair | 39 | 6.92e-02 | -0.168000 | 0.361000 |
Translesion synthesis by POLI | 15 | 2.59e-01 | -0.168000 | 0.597000 |
Transport of Mature mRNA derived from an Intron-Containing Transcript | 46 | 4.95e-02 | -0.168000 | 0.321000 |
Degradation of DVL | 45 | 5.25e-02 | -0.167000 | 0.328000 |
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | 31 | 1.08e-01 | -0.167000 | 0.428000 |
rRNA modification in the nucleus and cytosol | 44 | 5.56e-02 | -0.167000 | 0.337000 |
Diseases of carbohydrate metabolism | 23 | 1.67e-01 | 0.167000 | 0.514000 |
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | 79 | 1.07e-02 | -0.167000 | 0.160000 |
Amplification of signal from the kinetochores | 79 | 1.07e-02 | -0.167000 | 0.160000 |
Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 16 | 2.51e-01 | -0.166000 | 0.583000 |
ER to Golgi Anterograde Transport | 99 | 4.62e-03 | -0.165000 | 0.117000 |
Extension of Telomeres | 40 | 7.17e-02 | -0.165000 | 0.363000 |
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | 43 | 6.21e-02 | -0.165000 | 0.346000 |
RHOG GTPase cycle | 44 | 5.92e-02 | 0.165000 | 0.342000 |
Telomere Maintenance | 53 | 3.85e-02 | -0.165000 | 0.276000 |
Nuclear Pore Complex (NPC) Disassembly | 32 | 1.09e-01 | -0.164000 | 0.428000 |
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A | 41 | 6.98e-02 | -0.164000 | 0.361000 |
p53-Independent DNA Damage Response | 41 | 6.98e-02 | -0.164000 | 0.361000 |
p53-Independent G1/S DNA damage checkpoint | 41 | 6.98e-02 | -0.164000 | 0.361000 |
ADP signalling through P2Y purinoceptor 1 | 12 | 3.27e-01 | 0.163000 | 0.644000 |
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | 21 | 1.97e-01 | 0.163000 | 0.537000 |
Interleukin-1 signaling | 72 | 1.74e-02 | -0.162000 | 0.208000 |
Pausing and recovery of Tat-mediated HIV elongation | 22 | 1.88e-01 | -0.162000 | 0.531000 |
Tat-mediated HIV elongation arrest and recovery | 22 | 1.88e-01 | -0.162000 | 0.531000 |
Synthesis of glycosylphosphatidylinositol (GPI) | 14 | 2.93e-01 | -0.162000 | 0.616000 |
EML4 and NUDC in mitotic spindle formation | 83 | 1.08e-02 | -0.162000 | 0.160000 |
Defective pyroptosis | 10 | 3.75e-01 | -0.162000 | 0.664000 |
SCF(Skp2)-mediated degradation of p27/p21 | 49 | 5.07e-02 | -0.162000 | 0.321000 |
Vpu mediated degradation of CD4 | 40 | 7.78e-02 | -0.161000 | 0.380000 |
Disassembly of the destruction complex and recruitment of AXIN to the membrane | 26 | 1.55e-01 | 0.161000 | 0.493000 |
Cytochrome P450 - arranged by substrate type | 14 | 2.99e-01 | 0.160000 | 0.618000 |
Aquaporin-mediated transport | 19 | 2.29e-01 | 0.160000 | 0.565000 |
Oncogene Induced Senescence | 27 | 1.54e-01 | -0.159000 | 0.491000 |
PI3K/AKT Signaling in Cancer | 51 | 5.05e-02 | -0.159000 | 0.321000 |
Complex I biogenesis | 38 | 9.15e-02 | -0.158000 | 0.394000 |
G beta:gamma signalling through PI3Kgamma | 14 | 3.06e-01 | 0.158000 | 0.629000 |
TAK1-dependent IKK and NF-kappa-B activation | 17 | 2.61e-01 | -0.158000 | 0.598000 |
Cellular response to heat stress | 76 | 1.80e-02 | -0.157000 | 0.209000 |
HCMV Early Events | 48 | 6.09e-02 | -0.157000 | 0.343000 |
APC truncation mutants have impaired AXIN binding | 12 | 3.48e-01 | 0.156000 | 0.652000 |
AXIN missense mutants destabilize the destruction complex | 12 | 3.48e-01 | 0.156000 | 0.652000 |
Signaling by AMER1 mutants | 12 | 3.48e-01 | 0.156000 | 0.652000 |
Signaling by APC mutants | 12 | 3.48e-01 | 0.156000 | 0.652000 |
Signaling by AXIN mutants | 12 | 3.48e-01 | 0.156000 | 0.652000 |
Truncations of AMER1 destabilize the destruction complex | 12 | 3.48e-01 | 0.156000 | 0.652000 |
RAF activation | 28 | 1.53e-01 | 0.156000 | 0.488000 |
Negative regulation of NOTCH4 signaling | 45 | 7.00e-02 | -0.156000 | 0.361000 |
Cell Cycle Checkpoints | 208 | 1.12e-04 | -0.156000 | 0.019200 |
Regulation of TNFR1 signaling | 30 | 1.41e-01 | -0.156000 | 0.474000 |
RHO GTPases Activate ROCKs | 13 | 3.32e-01 | -0.155000 | 0.645000 |
Heme signaling | 25 | 1.79e-01 | 0.155000 | 0.523000 |
Calnexin/calreticulin cycle | 23 | 1.97e-01 | -0.155000 | 0.537000 |
HSF1-dependent transactivation | 25 | 1.79e-01 | -0.155000 | 0.523000 |
RAS processing | 13 | 3.34e-01 | 0.155000 | 0.645000 |
Signaling by Activin | 11 | 3.76e-01 | 0.154000 | 0.664000 |
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | 49 | 6.30e-02 | -0.154000 | 0.349000 |
Telomere C-strand (Lagging Strand) Synthesis | 27 | 1.67e-01 | -0.154000 | 0.514000 |
Viral Messenger RNA Synthesis | 39 | 9.87e-02 | -0.153000 | 0.410000 |
tRNA modification in the nucleus and cytosol | 30 | 1.48e-01 | -0.153000 | 0.482000 |
Export of Viral Ribonucleoproteins from Nucleus | 29 | 1.56e-01 | -0.152000 | 0.495000 |
Polymerase switching on the C-strand of the telomere | 20 | 2.39e-01 | -0.152000 | 0.579000 |
Arachidonic acid metabolism | 19 | 2.51e-01 | 0.152000 | 0.583000 |
TNF signaling | 35 | 1.20e-01 | -0.152000 | 0.444000 |
Apoptotic factor-mediated response | 14 | 3.25e-01 | 0.152000 | 0.643000 |
ISG15 antiviral mechanism | 66 | 3.33e-02 | -0.152000 | 0.264000 |
Nonhomologous End-Joining (NHEJ) | 27 | 1.73e-01 | -0.152000 | 0.517000 |
Degradation of GLI2 by the proteasome | 47 | 7.35e-02 | -0.151000 | 0.366000 |
GLI3 is processed to GLI3R by the proteasome | 47 | 7.35e-02 | -0.151000 | 0.366000 |
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | 37 | 1.13e-01 | -0.151000 | 0.434000 |
ABC-family proteins mediated transport | 69 | 3.09e-02 | -0.151000 | 0.261000 |
Class I peroxisomal membrane protein import | 17 | 2.83e-01 | -0.150000 | 0.614000 |
RND3 GTPase cycle | 29 | 1.61e-01 | 0.150000 | 0.508000 |
NS1 Mediated Effects on Host Pathways | 36 | 1.19e-01 | -0.150000 | 0.444000 |
Degradation of GLI1 by the proteasome | 48 | 7.31e-02 | -0.150000 | 0.366000 |
AURKA Activation by TPX2 | 55 | 5.56e-02 | -0.149000 | 0.337000 |
Metalloprotease DUBs | 16 | 3.01e-01 | -0.149000 | 0.620000 |
RAC1 GTPase cycle | 99 | 1.07e-02 | 0.149000 | 0.160000 |
Cell-Cell communication | 41 | 1.00e-01 | 0.148000 | 0.413000 |
Antiviral mechanism by IFN-stimulated genes | 72 | 3.00e-02 | -0.148000 | 0.261000 |
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | 26 | 1.92e-01 | -0.148000 | 0.534000 |
Regulation of Glucokinase by Glucokinase Regulatory Protein | 26 | 1.92e-01 | -0.148000 | 0.534000 |
Signaling by GPCR | 187 | 5.27e-04 | 0.148000 | 0.038500 |
CDC42 GTPase cycle | 88 | 1.69e-02 | 0.148000 | 0.203000 |
HIV elongation arrest and recovery | 23 | 2.23e-01 | -0.147000 | 0.557000 |
Pausing and recovery of HIV elongation | 23 | 2.23e-01 | -0.147000 | 0.557000 |
Basigin interactions | 13 | 3.62e-01 | 0.146000 | 0.661000 |
Regulated Necrosis | 41 | 1.06e-01 | -0.146000 | 0.426000 |
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. | 74 | 3.03e-02 | -0.146000 | 0.261000 |
tRNA processing in the nucleus | 52 | 6.90e-02 | -0.146000 | 0.361000 |
Interleukin-7 signaling | 14 | 3.46e-01 | 0.146000 | 0.652000 |
Anchoring of the basal body to the plasma membrane | 72 | 3.30e-02 | -0.146000 | 0.264000 |
Interconversion of nucleotide di- and triphosphates | 18 | 2.86e-01 | 0.145000 | 0.614000 |
Mitotic Prophase | 70 | 3.63e-02 | -0.145000 | 0.272000 |
Metabolism of non-coding RNA | 45 | 9.29e-02 | -0.145000 | 0.394000 |
snRNP Assembly | 45 | 9.29e-02 | -0.145000 | 0.394000 |
NIK–>noncanonical NF-kB signaling | 46 | 9.02e-02 | -0.145000 | 0.394000 |
Adrenaline,noradrenaline inhibits insulin secretion | 12 | 3.86e-01 | 0.144000 | 0.673000 |
Signaling by NTRK3 (TRKC) | 10 | 4.29e-01 | 0.144000 | 0.714000 |
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 33 | 1.52e-01 | 0.144000 | 0.487000 |
SUMOylation of ubiquitinylation proteins | 35 | 1.40e-01 | -0.144000 | 0.474000 |
tRNA processing | 86 | 2.12e-02 | -0.144000 | 0.219000 |
Regulation of RUNX3 expression and activity | 46 | 9.21e-02 | -0.144000 | 0.394000 |
Respiratory electron transport | 73 | 3.48e-02 | -0.143000 | 0.268000 |
Beta-catenin phosphorylation cascade | 15 | 3.39e-01 | 0.143000 | 0.649000 |
Intraflagellar transport | 30 | 1.77e-01 | -0.143000 | 0.521000 |
Transport of the SLBP independent Mature mRNA | 30 | 1.78e-01 | -0.142000 | 0.522000 |
Sensory Perception | 61 | 5.55e-02 | 0.142000 | 0.337000 |
Metabolism of folate and pterines | 11 | 4.16e-01 | -0.142000 | 0.699000 |
Signaling by SCF-KIT | 31 | 1.73e-01 | 0.141000 | 0.518000 |
SUMOylation of transcription cofactors | 35 | 1.49e-01 | 0.141000 | 0.483000 |
Activation of GABAB receptors | 15 | 3.45e-01 | 0.141000 | 0.652000 |
GABA B receptor activation | 15 | 3.45e-01 | 0.141000 | 0.652000 |
Mitotic Spindle Checkpoint | 91 | 2.06e-02 | -0.141000 | 0.219000 |
Kinesins | 31 | 1.77e-01 | -0.140000 | 0.521000 |
Regulation of PLK1 Activity at G2/M Transition | 67 | 4.73e-02 | -0.140000 | 0.316000 |
TP53 Regulates Transcription of Cell Death Genes | 29 | 1.91e-01 | 0.140000 | 0.534000 |
Regulation of PTEN stability and activity | 52 | 8.06e-02 | -0.140000 | 0.383000 |
SARS-CoV-2-host interactions | 142 | 4.06e-03 | -0.140000 | 0.117000 |
Infection with Mycobacterium tuberculosis | 20 | 2.80e-01 | -0.140000 | 0.614000 |
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | 43 | 1.14e-01 | -0.140000 | 0.434000 |
COPI-dependent Golgi-to-ER retrograde traffic | 62 | 5.94e-02 | -0.139000 | 0.342000 |
Regulation of TP53 Activity | 128 | 6.96e-03 | -0.139000 | 0.140000 |
DNA strand elongation | 27 | 2.14e-01 | -0.138000 | 0.551000 |
Disorders of transmembrane transporters | 103 | 1.59e-02 | -0.138000 | 0.197000 |
Uptake and actions of bacterial toxins | 18 | 3.13e-01 | 0.137000 | 0.630000 |
Triglyceride catabolism | 11 | 4.30e-01 | 0.137000 | 0.714000 |
Metabolism of RNA | 509 | 1.78e-07 | -0.137000 | 0.000208 |
E3 ubiquitin ligases ubiquitinate target proteins | 40 | 1.36e-01 | -0.136000 | 0.466000 |
Drug ADME | 25 | 2.41e-01 | 0.136000 | 0.579000 |
RMTs methylate histone arginines | 24 | 2.51e-01 | 0.135000 | 0.583000 |
XBP1(S) activates chaperone genes | 39 | 1.45e-01 | -0.135000 | 0.477000 |
HATs acetylate histones | 53 | 9.02e-02 | -0.135000 | 0.394000 |
Signaling by EGFR in Cancer | 16 | 3.51e-01 | -0.135000 | 0.654000 |
Synthesis of IP3 and IP4 in the cytosol | 16 | 3.53e-01 | 0.134000 | 0.655000 |
Signaling by EGFR | 35 | 1.70e-01 | -0.134000 | 0.514000 |
APC/C:Cdc20 mediated degradation of mitotic proteins | 58 | 7.85e-02 | -0.134000 | 0.380000 |
Vpr-mediated nuclear import of PICs | 30 | 2.05e-01 | -0.134000 | 0.548000 |
GPCR downstream signalling | 170 | 2.91e-03 | 0.133000 | 0.113000 |
UCH proteinases | 69 | 5.66e-02 | -0.133000 | 0.338000 |
Golgi-to-ER retrograde transport | 90 | 3.00e-02 | -0.133000 | 0.261000 |
Biological oxidations | 73 | 5.07e-02 | 0.132000 | 0.321000 |
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 59 | 7.90e-02 | -0.132000 | 0.380000 |
G alpha (z) signalling events | 22 | 2.85e-01 | 0.132000 | 0.614000 |
Autodegradation of Cdh1 by Cdh1:APC/C | 50 | 1.09e-01 | -0.131000 | 0.428000 |
Signaling by FLT3 ITD and TKD mutants | 12 | 4.32e-01 | 0.131000 | 0.716000 |
Intra-Golgi traffic | 37 | 1.69e-01 | -0.131000 | 0.514000 |
Transport of Ribonucleoproteins into the Host Nucleus | 28 | 2.33e-01 | -0.130000 | 0.572000 |
Intra-Golgi and retrograde Golgi-to-ER traffic | 150 | 6.26e-03 | -0.130000 | 0.133000 |
M Phase | 273 | 2.48e-04 | -0.130000 | 0.024200 |
Interleukin-1 family signaling | 89 | 3.51e-02 | -0.130000 | 0.268000 |
FGFR2 mutant receptor activation | 16 | 3.71e-01 | -0.129000 | 0.662000 |
Interleukin-2 family signaling | 27 | 2.46e-01 | 0.129000 | 0.582000 |
Signaling by FGFR2 IIIa TM | 15 | 3.87e-01 | -0.129000 | 0.673000 |
DNA Damage Recognition in GG-NER | 35 | 1.88e-01 | -0.129000 | 0.531000 |
MAPK6/MAPK4 signaling | 63 | 7.79e-02 | -0.129000 | 0.380000 |
RHOQ GTPase cycle | 36 | 1.83e-01 | 0.128000 | 0.529000 |
Interactions of Vpr with host cellular proteins | 31 | 2.18e-01 | -0.128000 | 0.553000 |
Signaling by FGFR2 | 47 | 1.29e-01 | -0.128000 | 0.456000 |
Cross-presentation of soluble exogenous antigens (endosomes) | 35 | 1.91e-01 | -0.128000 | 0.534000 |
Cell Cycle | 483 | 2.25e-06 | -0.127000 | 0.001320 |
Regulation of IFNA/IFNB signaling | 11 | 4.65e-01 | 0.127000 | 0.741000 |
Signaling by FGFR3 | 24 | 2.81e-01 | -0.127000 | 0.614000 |
Signaling by FGFR4 | 24 | 2.81e-01 | -0.127000 | 0.614000 |
Insulin processing | 15 | 3.95e-01 | 0.127000 | 0.682000 |
Transport of the SLBP Dependant Mature mRNA | 31 | 2.23e-01 | -0.127000 | 0.557000 |
Glucagon signaling in metabolic regulation | 14 | 4.13e-01 | 0.126000 | 0.699000 |
Ca2+ pathway | 34 | 2.03e-01 | 0.126000 | 0.543000 |
Peroxisomal lipid metabolism | 18 | 3.61e-01 | -0.124000 | 0.661000 |
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | 13 | 4.38e-01 | -0.124000 | 0.718000 |
G alpha (q) signalling events | 67 | 7.99e-02 | 0.124000 | 0.383000 |
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | 57 | 1.06e-01 | -0.124000 | 0.426000 |
RHO GTPase Effectors | 182 | 4.27e-03 | -0.123000 | 0.117000 |
Negative regulation of MET activity | 14 | 4.24e-01 | -0.123000 | 0.707000 |
RNA Polymerase II Pre-transcription Events | 61 | 9.67e-02 | -0.123000 | 0.404000 |
Retrograde transport at the Trans-Golgi-Network | 42 | 1.68e-01 | -0.123000 | 0.514000 |
Post-translational protein phosphorylation | 32 | 2.28e-01 | 0.123000 | 0.565000 |
Vasopressin regulates renal water homeostasis via Aquaporins | 18 | 3.67e-01 | 0.123000 | 0.661000 |
APC/C:Cdc20 mediated degradation of Securin | 51 | 1.30e-01 | -0.123000 | 0.456000 |
Heparan sulfate/heparin (HS-GAG) metabolism | 22 | 3.20e-01 | 0.122000 | 0.640000 |
Dectin-1 mediated noncanonical NF-kB signaling | 47 | 1.47e-01 | -0.122000 | 0.480000 |
SUMOylation of SUMOylation proteins | 30 | 2.46e-01 | -0.122000 | 0.582000 |
Transport to the Golgi and subsequent modification | 122 | 2.02e-02 | -0.122000 | 0.219000 |
Recruitment of NuMA to mitotic centrosomes | 59 | 1.05e-01 | -0.122000 | 0.426000 |
NEP/NS2 Interacts with the Cellular Export Machinery | 28 | 2.65e-01 | -0.122000 | 0.600000 |
Interleukin receptor SHC signaling | 15 | 4.15e-01 | 0.122000 | 0.699000 |
TICAM1-dependent activation of IRF3/IRF7 | 12 | 4.67e-01 | -0.121000 | 0.741000 |
Transcriptional regulation by RUNX3 | 70 | 8.06e-02 | -0.121000 | 0.383000 |
Cholesterol biosynthesis | 20 | 3.50e-01 | -0.121000 | 0.653000 |
O-linked glycosylation | 36 | 2.10e-01 | 0.121000 | 0.551000 |
Fatty acyl-CoA biosynthesis | 19 | 3.64e-01 | 0.120000 | 0.661000 |
Pyroptosis | 17 | 3.91e-01 | 0.120000 | 0.677000 |
FOXO-mediated transcription | 45 | 1.65e-01 | 0.120000 | 0.513000 |
Transport of bile salts and organic acids, metal ions and amine compounds | 31 | 2.50e-01 | 0.119000 | 0.583000 |
Orc1 removal from chromatin | 53 | 1.34e-01 | -0.119000 | 0.461000 |
Regulation of Apoptosis | 42 | 1.82e-01 | -0.119000 | 0.527000 |
RNA Polymerase III Transcription Initiation From Type 1 Promoter | 27 | 2.86e-01 | -0.119000 | 0.614000 |
Clathrin-mediated endocytosis | 82 | 6.44e-02 | -0.118000 | 0.352000 |
Centrosome maturation | 60 | 1.14e-01 | -0.118000 | 0.434000 |
Recruitment of mitotic centrosome proteins and complexes | 60 | 1.14e-01 | -0.118000 | 0.434000 |
Protein-protein interactions at synapses | 31 | 2.56e-01 | 0.118000 | 0.590000 |
Signaling by FGFR1 in disease | 23 | 3.28e-01 | 0.118000 | 0.644000 |
Regulation of RUNX2 expression and activity | 54 | 1.35e-01 | -0.118000 | 0.463000 |
COPI-independent Golgi-to-ER retrograde traffic | 28 | 2.81e-01 | -0.118000 | 0.614000 |
Loss of Nlp from mitotic centrosomes | 52 | 1.43e-01 | -0.118000 | 0.474000 |
Loss of proteins required for interphase microtubule organization from the centrosome | 52 | 1.43e-01 | -0.118000 | 0.474000 |
Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 56 | 1.29e-01 | -0.118000 | 0.454000 |
Regulation of MECP2 expression and activity | 20 | 3.64e-01 | 0.117000 | 0.661000 |
IRE1alpha activates chaperones | 40 | 2.00e-01 | -0.117000 | 0.539000 |
Smooth Muscle Contraction | 19 | 3.77e-01 | -0.117000 | 0.664000 |
mRNA Splicing - Minor Pathway | 43 | 1.85e-01 | -0.117000 | 0.530000 |
Maturation of nucleoprotein | 11 | 5.05e-01 | 0.116000 | 0.758000 |
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | 57 | 1.30e-01 | -0.116000 | 0.456000 |
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models | 20 | 3.69e-01 | 0.116000 | 0.661000 |
Neurodegenerative Diseases | 20 | 3.69e-01 | 0.116000 | 0.661000 |
Cilium Assembly | 135 | 2.06e-02 | -0.116000 | 0.219000 |
Cargo recognition for clathrin-mediated endocytosis | 57 | 1.31e-01 | -0.116000 | 0.457000 |
Rab regulation of trafficking | 81 | 7.27e-02 | -0.116000 | 0.366000 |
Synthesis of PIPs at the early endosome membrane | 12 | 4.89e-01 | -0.115000 | 0.751000 |
Regulation of expression of SLITs and ROBOs | 118 | 3.18e-02 | -0.115000 | 0.264000 |
rRNA processing | 155 | 1.47e-02 | -0.114000 | 0.195000 |
HCMV Late Events | 47 | 1.77e-01 | -0.114000 | 0.521000 |
Opioid Signalling | 49 | 1.70e-01 | 0.114000 | 0.514000 |
SUMOylation of DNA methylation proteins | 14 | 4.63e-01 | 0.113000 | 0.741000 |
mRNA decay by 5’ to 3’ exoribonuclease | 14 | 4.64e-01 | -0.113000 | 0.741000 |
DNA Repair | 234 | 3.08e-03 | -0.113000 | 0.116000 |
Major pathway of rRNA processing in the nucleolus and cytosol | 145 | 2.06e-02 | -0.112000 | 0.219000 |
G alpha (s) signalling events | 38 | 2.33e-01 | 0.112000 | 0.572000 |
APC/C-mediated degradation of cell cycle proteins | 70 | 1.07e-01 | -0.112000 | 0.426000 |
Regulation of mitotic cell cycle | 70 | 1.07e-01 | -0.112000 | 0.426000 |
DNA Damage/Telomere Stress Induced Senescence | 24 | 3.45e-01 | -0.111000 | 0.652000 |
FGFR2 alternative splicing | 22 | 3.66e-01 | -0.111000 | 0.661000 |
Azathioprine ADME | 15 | 4.55e-01 | 0.111000 | 0.736000 |
SCF-beta-TrCP mediated degradation of Emi1 | 44 | 2.03e-01 | -0.111000 | 0.543000 |
Translation | 228 | 4.14e-03 | -0.111000 | 0.117000 |
Cell recruitment (pro-inflammatory response) | 15 | 4.57e-01 | 0.111000 | 0.737000 |
Purinergic signaling in leishmaniasis infection | 15 | 4.57e-01 | 0.111000 | 0.737000 |
Transcriptional regulation by small RNAs | 41 | 2.20e-01 | -0.111000 | 0.557000 |
HCMV Infection | 67 | 1.18e-01 | -0.111000 | 0.443000 |
CTNNB1 S33 mutants aren’t phosphorylated | 13 | 4.91e-01 | 0.110000 | 0.751000 |
CTNNB1 S37 mutants aren’t phosphorylated | 13 | 4.91e-01 | 0.110000 | 0.751000 |
CTNNB1 S45 mutants aren’t phosphorylated | 13 | 4.91e-01 | 0.110000 | 0.751000 |
CTNNB1 T41 mutants aren’t phosphorylated | 13 | 4.91e-01 | 0.110000 | 0.751000 |
Signaling by CTNNB1 phospho-site mutants | 13 | 4.91e-01 | 0.110000 | 0.751000 |
Signaling by GSK3beta mutants | 13 | 4.91e-01 | 0.110000 | 0.751000 |
RAB geranylgeranylation | 37 | 2.47e-01 | -0.110000 | 0.582000 |
Mitotic Metaphase and Anaphase | 181 | 1.11e-02 | -0.110000 | 0.161000 |
Peptide hormone metabolism | 27 | 3.23e-01 | 0.110000 | 0.643000 |
G2/M Transition | 145 | 2.30e-02 | -0.110000 | 0.226000 |
PINK1-PRKN Mediated Mitophagy | 19 | 4.09e-01 | 0.109000 | 0.697000 |
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | 10 | 5.50e-01 | -0.109000 | 0.793000 |
TP53 Regulates Transcription of DNA Repair Genes | 45 | 2.07e-01 | -0.109000 | 0.548000 |
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | 14 | 4.82e-01 | -0.109000 | 0.749000 |
Signaling by Ligand-Responsive EGFR Variants in Cancer | 14 | 4.82e-01 | -0.109000 | 0.749000 |
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | 10 | 5.52e-01 | -0.109000 | 0.795000 |
RHOD GTPase cycle | 32 | 2.89e-01 | 0.108000 | 0.614000 |
SUMOylation of RNA binding proteins | 40 | 2.37e-01 | -0.108000 | 0.579000 |
rRNA processing in the nucleus and cytosol | 151 | 2.24e-02 | -0.108000 | 0.223000 |
RHOJ GTPase cycle | 34 | 2.76e-01 | 0.108000 | 0.614000 |
Mitotic G2-G2/M phases | 147 | 2.44e-02 | -0.108000 | 0.236000 |
Asparagine N-linked glycosylation | 214 | 6.85e-03 | -0.108000 | 0.140000 |
Lysosome Vesicle Biogenesis | 24 | 3.62e-01 | 0.108000 | 0.661000 |
Mitotic Anaphase | 180 | 1.34e-02 | -0.107000 | 0.180000 |
RNA Polymerase III Transcription Initiation From Type 2 Promoter | 26 | 3.44e-01 | -0.107000 | 0.652000 |
FCERI mediated MAPK activation | 21 | 3.96e-01 | 0.107000 | 0.682000 |
Pre-NOTCH Transcription and Translation | 27 | 3.36e-01 | -0.107000 | 0.647000 |
Metabolism of water-soluble vitamins and cofactors | 76 | 1.08e-01 | -0.107000 | 0.428000 |
Cell Cycle, Mitotic | 390 | 3.55e-04 | -0.107000 | 0.029600 |
Mismatch Repair | 13 | 5.07e-01 | -0.106000 | 0.760000 |
Unfolded Protein Response (UPR) | 72 | 1.20e-01 | -0.106000 | 0.444000 |
Signaling by FLT3 fusion proteins | 15 | 4.78e-01 | 0.106000 | 0.748000 |
G1/S-Specific Transcription | 23 | 3.80e-01 | 0.106000 | 0.667000 |
NOTCH3 Activation and Transmission of Signal to the Nucleus | 15 | 4.79e-01 | -0.106000 | 0.748000 |
Fanconi Anemia Pathway | 28 | 3.34e-01 | -0.106000 | 0.645000 |
Activation of BH3-only proteins | 25 | 3.61e-01 | 0.106000 | 0.661000 |
VEGFR2 mediated vascular permeability | 21 | 4.05e-01 | 0.105000 | 0.693000 |
SUMOylation of intracellular receptors | 19 | 4.29e-01 | 0.105000 | 0.714000 |
Signaling by NOTCH4 | 65 | 1.45e-01 | -0.105000 | 0.477000 |
G-protein beta:gamma signalling | 18 | 4.43e-01 | 0.105000 | 0.725000 |
TGF-beta receptor signaling activates SMADs | 36 | 2.81e-01 | 0.104000 | 0.614000 |
Transport of vitamins, nucleosides, and related molecules | 19 | 4.34e-01 | 0.104000 | 0.716000 |
Signaling by ROBO receptors | 146 | 3.13e-02 | -0.104000 | 0.261000 |
N-glycan antennae elongation in the medial/trans-Golgi | 18 | 4.48e-01 | 0.103000 | 0.729000 |
Thrombin signalling through proteinase activated receptors (PARs) | 16 | 4.74e-01 | 0.103000 | 0.748000 |
Dual Incision in GG-NER | 34 | 2.98e-01 | -0.103000 | 0.618000 |
Response of Mtb to phagocytosis | 19 | 4.37e-01 | -0.103000 | 0.718000 |
FGFR1 mutant receptor activation | 19 | 4.38e-01 | 0.103000 | 0.718000 |
Signaling by FGFR | 50 | 2.09e-01 | -0.103000 | 0.550000 |
Cap-dependent Translation Initiation | 91 | 9.16e-02 | -0.103000 | 0.394000 |
Eukaryotic Translation Initiation | 91 | 9.16e-02 | -0.103000 | 0.394000 |
Cell surface interactions at the vascular wall | 54 | 1.93e-01 | 0.102000 | 0.535000 |
Gap-filling DNA repair synthesis and ligation in TC-NER | 54 | 1.95e-01 | -0.102000 | 0.537000 |
Degradation of AXIN | 44 | 2.42e-01 | -0.102000 | 0.579000 |
Transcription of the HIV genome | 50 | 2.13e-01 | -0.102000 | 0.551000 |
Activation of NF-kappaB in B cells | 53 | 2.01e-01 | -0.102000 | 0.541000 |
Platelet calcium homeostasis | 16 | 4.81e-01 | 0.102000 | 0.749000 |
Heme biosynthesis | 10 | 5.78e-01 | -0.102000 | 0.816000 |
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | 28 | 3.55e-01 | -0.101000 | 0.656000 |
Host Interactions of HIV factors | 100 | 8.16e-02 | -0.101000 | 0.384000 |
HIV Transcription Initiation | 36 | 2.95e-01 | -0.101000 | 0.616000 |
RNA Polymerase II HIV Promoter Escape | 36 | 2.95e-01 | -0.101000 | 0.616000 |
RNA Polymerase II Promoter Escape | 36 | 2.95e-01 | -0.101000 | 0.616000 |
RNA Polymerase II Transcription Initiation | 36 | 2.95e-01 | -0.101000 | 0.616000 |
RNA Polymerase II Transcription Initiation And Promoter Clearance | 36 | 2.95e-01 | -0.101000 | 0.616000 |
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 36 | 2.95e-01 | -0.101000 | 0.616000 |
Diseases associated with the TLR signaling cascade | 15 | 5.00e-01 | -0.101000 | 0.755000 |
Diseases of Immune System | 15 | 5.00e-01 | -0.101000 | 0.755000 |
Signaling by BRAF and RAF1 fusions | 41 | 2.65e-01 | 0.101000 | 0.600000 |
Visual phototransduction | 31 | 3.34e-01 | 0.100000 | 0.645000 |
Retinoid metabolism and transport | 10 | 5.83e-01 | 0.100000 | 0.817000 |
Formation of Incision Complex in GG-NER | 35 | 3.06e-01 | 0.100000 | 0.628000 |
Deadenylation-dependent mRNA decay | 50 | 2.23e-01 | -0.099700 | 0.557000 |
ADORA2B mediated anti-inflammatory cytokines production | 28 | 3.63e-01 | 0.099400 | 0.661000 |
CDK-mediated phosphorylation and removal of Cdc6 | 56 | 1.99e-01 | -0.099300 | 0.539000 |
Assembly of the pre-replicative complex | 64 | 1.70e-01 | -0.099300 | 0.514000 |
Plasma lipoprotein assembly, remodeling, and clearance | 35 | 3.10e-01 | -0.099300 | 0.630000 |
Base-Excision Repair, AP Site Formation | 16 | 4.92e-01 | -0.099200 | 0.751000 |
SARS-CoV-2 Infection | 203 | 1.57e-02 | -0.098900 | 0.197000 |
MAP3K8 (TPL2)-dependent MAPK1/3 activation | 13 | 5.38e-01 | -0.098700 | 0.789000 |
Diseases associated with glycosaminoglycan metabolism | 16 | 4.95e-01 | 0.098500 | 0.755000 |
ERK/MAPK targets | 16 | 4.96e-01 | -0.098300 | 0.755000 |
Degradation of the extracellular matrix | 28 | 3.70e-01 | 0.098000 | 0.661000 |
Signaling by ERBB2 | 33 | 3.31e-01 | -0.097800 | 0.645000 |
Interferon Signaling | 130 | 5.59e-02 | -0.097500 | 0.337000 |
Downstream signal transduction | 20 | 4.51e-01 | 0.097400 | 0.733000 |
Abortive elongation of HIV-1 transcript in the absence of Tat | 18 | 4.75e-01 | -0.097200 | 0.748000 |
RNA Polymerase III Transcription Initiation | 35 | 3.21e-01 | -0.097000 | 0.640000 |
Collagen biosynthesis and modifying enzymes | 13 | 5.46e-01 | 0.096800 | 0.791000 |
Thromboxane signalling through TP receptor | 11 | 5.79e-01 | 0.096700 | 0.816000 |
PIP3 activates AKT signaling | 172 | 2.97e-02 | -0.096600 | 0.261000 |
Listeria monocytogenes entry into host cells | 14 | 5.32e-01 | -0.096500 | 0.784000 |
Interleukin-15 signaling | 11 | 5.82e-01 | 0.095800 | 0.817000 |
SRP-dependent cotranslational protein targeting to membrane | 86 | 1.26e-01 | -0.095600 | 0.452000 |
Signaling by NOTCH1 | 51 | 2.39e-01 | 0.095400 | 0.579000 |
Activation of ATR in response to replication stress | 29 | 3.76e-01 | -0.095100 | 0.664000 |
Metabolism of polyamines | 44 | 2.76e-01 | -0.095000 | 0.614000 |
FCERI mediated NF-kB activation | 59 | 2.08e-01 | -0.094900 | 0.550000 |
CLEC7A (Dectin-1) signaling | 77 | 1.52e-01 | -0.094700 | 0.487000 |
The citric acid (TCA) cycle and respiratory electron transport | 109 | 8.90e-02 | -0.094600 | 0.394000 |
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 37 | 3.20e-01 | -0.094500 | 0.640000 |
Inactivation of APC/C via direct inhibition of the APC/C complex | 16 | 5.16e-01 | 0.093800 | 0.769000 |
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | 16 | 5.16e-01 | 0.093800 | 0.769000 |
L13a-mediated translational silencing of Ceruloplasmin expression | 83 | 1.41e-01 | -0.093600 | 0.474000 |
SLC-mediated transmembrane transport | 91 | 1.24e-01 | 0.093600 | 0.450000 |
Constitutive Signaling by Aberrant PI3K in Cancer | 27 | 4.02e-01 | -0.093300 | 0.690000 |
Nicotinate metabolism | 16 | 5.20e-01 | 0.092900 | 0.774000 |
Oxidative Stress Induced Senescence | 51 | 2.52e-01 | -0.092800 | 0.584000 |
RHOBTB1 GTPase cycle | 18 | 4.99e-01 | 0.092200 | 0.755000 |
NOTCH2 Activation and Transmission of Signal to the Nucleus | 12 | 5.81e-01 | -0.092100 | 0.816000 |
Ca-dependent events | 18 | 4.99e-01 | 0.092100 | 0.755000 |
Hedgehog ‘off’ state | 70 | 1.84e-01 | -0.091900 | 0.530000 |
Metabolism of cofactors | 16 | 5.25e-01 | 0.091900 | 0.779000 |
RHO GTPases activate PKNs | 26 | 4.20e-01 | -0.091400 | 0.702000 |
NOTCH4 Intracellular Domain Regulates Transcription | 14 | 5.54e-01 | -0.091300 | 0.796000 |
Oncogenic MAPK signaling | 54 | 2.48e-01 | 0.091100 | 0.583000 |
Gene Silencing by RNA | 56 | 2.40e-01 | -0.091000 | 0.579000 |
CaM pathway | 17 | 5.16e-01 | 0.090900 | 0.769000 |
Calmodulin induced events | 17 | 5.16e-01 | 0.090900 | 0.769000 |
Cellular response to hypoxia | 56 | 2.42e-01 | -0.090500 | 0.579000 |
Triglyceride metabolism | 15 | 5.44e-01 | 0.090500 | 0.791000 |
Mitophagy | 23 | 4.53e-01 | 0.090400 | 0.734000 |
PTEN Regulation | 104 | 1.12e-01 | -0.090400 | 0.434000 |
Formation of a pool of free 40S subunits | 75 | 1.79e-01 | -0.089900 | 0.523000 |
Suppression of phagosomal maturation | 11 | 6.06e-01 | -0.089900 | 0.828000 |
Influenza Infection | 126 | 8.28e-02 | -0.089800 | 0.386000 |
Nuclear Envelope Breakdown | 45 | 2.99e-01 | -0.089600 | 0.618000 |
Regulation of RAS by GAPs | 52 | 2.65e-01 | -0.089400 | 0.600000 |
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 15 | 5.50e-01 | -0.089200 | 0.793000 |
Depolymerisation of the Nuclear Lamina | 11 | 6.10e-01 | 0.088800 | 0.830000 |
RAF-independent MAPK1/3 activation | 19 | 5.03e-01 | 0.088800 | 0.758000 |
Early Phase of HIV Life Cycle | 12 | 5.97e-01 | -0.088300 | 0.825000 |
Nuclear import of Rev protein | 29 | 4.11e-01 | -0.088200 | 0.698000 |
Synthesis of DNA | 93 | 1.43e-01 | -0.088100 | 0.474000 |
FLT3 signaling in disease | 23 | 4.65e-01 | -0.088100 | 0.741000 |
Organelle biogenesis and maintenance | 187 | 3.94e-02 | -0.087800 | 0.279000 |
Influenza Viral RNA Transcription and Replication | 109 | 1.14e-01 | -0.087800 | 0.434000 |
RND1 GTPase cycle | 29 | 4.14e-01 | 0.087700 | 0.699000 |
DNA Replication Pre-Initiation | 77 | 1.86e-01 | -0.087400 | 0.530000 |
Downstream TCR signaling | 64 | 2.28e-01 | -0.087200 | 0.565000 |
TRAF6 mediated IRF7 activation | 16 | 5.47e-01 | 0.087100 | 0.791000 |
Transport of inorganic cations/anions and amino acids/oligopeptides | 38 | 3.54e-01 | 0.086900 | 0.656000 |
RHOV GTPase cycle | 25 | 4.53e-01 | 0.086700 | 0.734000 |
SUMOylation of DNA damage response and repair proteins | 64 | 2.31e-01 | -0.086600 | 0.571000 |
Metabolic disorders of biological oxidation enzymes | 13 | 5.89e-01 | 0.086600 | 0.819000 |
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | 12 | 6.04e-01 | -0.086400 | 0.828000 |
GTP hydrolysis and joining of the 60S ribosomal subunit | 84 | 1.73e-01 | -0.086300 | 0.517000 |
Toll Like Receptor 4 (TLR4) Cascade | 86 | 1.68e-01 | -0.086200 | 0.514000 |
MyD88-independent TLR4 cascade | 71 | 2.13e-01 | -0.085700 | 0.551000 |
TRIF(TICAM1)-mediated TLR4 signaling | 71 | 2.13e-01 | -0.085700 | 0.551000 |
Anti-inflammatory response favouring Leishmania parasite infection | 47 | 3.10e-01 | 0.085600 | 0.630000 |
Leishmania parasite growth and survival | 47 | 3.10e-01 | 0.085600 | 0.630000 |
RET signaling | 22 | 4.87e-01 | 0.085600 | 0.751000 |
CTLA4 inhibitory signaling | 15 | 5.66e-01 | 0.085600 | 0.807000 |
Regulation of APC/C activators between G1/S and early anaphase | 64 | 2.38e-01 | -0.085400 | 0.579000 |
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 61 | 2.51e-01 | -0.085200 | 0.583000 |
Death Receptor Signalling | 86 | 1.74e-01 | -0.085000 | 0.518000 |
Muscle contraction | 63 | 2.47e-01 | 0.084400 | 0.583000 |
Ovarian tumor domain proteases | 29 | 4.32e-01 | -0.084300 | 0.716000 |
Signaling by RAF1 mutants | 25 | 4.68e-01 | 0.084000 | 0.741000 |
SUMOylation of DNA replication proteins | 41 | 3.53e-01 | -0.083900 | 0.655000 |
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | 13 | 6.01e-01 | 0.083900 | 0.827000 |
TP53 Regulates Metabolic Genes | 61 | 2.60e-01 | -0.083500 | 0.597000 |
Mitochondrial protein import | 40 | 3.65e-01 | -0.082900 | 0.661000 |
Cyclin A/B1/B2 associated events during G2/M transition | 22 | 5.04e-01 | -0.082400 | 0.758000 |
Metabolism of steroid hormones | 13 | 6.07e-01 | -0.082400 | 0.828000 |
Formation of RNA Pol II elongation complex | 45 | 3.40e-01 | -0.082300 | 0.649000 |
RNA Polymerase II Transcription Elongation | 45 | 3.40e-01 | -0.082300 | 0.649000 |
RNA Polymerase III Abortive And Retractive Initiation | 38 | 3.83e-01 | -0.081900 | 0.669000 |
RNA Polymerase III Transcription | 38 | 3.83e-01 | -0.081900 | 0.669000 |
Nuclear signaling by ERBB4 | 14 | 5.96e-01 | 0.081900 | 0.825000 |
L1CAM interactions | 34 | 4.11e-01 | 0.081500 | 0.698000 |
APC/C:Cdc20 mediated degradation of Cyclin B | 19 | 5.40e-01 | -0.081300 | 0.791000 |
SARS-CoV Infections | 257 | 2.62e-02 | -0.081100 | 0.241000 |
MAP kinase activation | 46 | 3.42e-01 | -0.081100 | 0.651000 |
Signaling by NOTCH2 | 18 | 5.53e-01 | -0.080900 | 0.795000 |
Bile acid and bile salt metabolism | 13 | 6.14e-01 | 0.080800 | 0.833000 |
Signaling by FGFR1 | 27 | 4.68e-01 | -0.080800 | 0.741000 |
RHOBTB2 GTPase cycle | 19 | 5.44e-01 | -0.080400 | 0.791000 |
DNA Replication | 100 | 1.66e-01 | -0.080400 | 0.514000 |
Gap junction trafficking and regulation | 10 | 6.62e-01 | 0.079900 | 0.863000 |
RUNX1 regulates transcription of genes involved in differentiation of HSCs | 53 | 3.16e-01 | -0.079700 | 0.635000 |
NOTCH1 Intracellular Domain Regulates Transcription | 37 | 4.03e-01 | 0.079500 | 0.691000 |
Extracellular matrix organization | 73 | 2.44e-01 | 0.079000 | 0.582000 |
Intracellular signaling by second messengers | 194 | 5.97e-02 | -0.078800 | 0.342000 |
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 10 | 6.67e-01 | -0.078600 | 0.863000 |
Intrinsic Pathway for Apoptosis | 43 | 3.73e-01 | 0.078600 | 0.664000 |
TNFR1-induced NFkappaB signaling pathway | 19 | 5.56e-01 | -0.078000 | 0.797000 |
Costimulation by the CD28 family | 41 | 3.88e-01 | 0.077900 | 0.674000 |
Aberrant regulation of mitotic exit in cancer due to RB1 defects | 15 | 6.02e-01 | 0.077800 | 0.827000 |
Non-integrin membrane-ECM interactions | 11 | 6.56e-01 | 0.077500 | 0.858000 |
Activation of HOX genes during differentiation | 37 | 4.17e-01 | -0.077300 | 0.699000 |
Activation of anterior HOX genes in hindbrain development during early embryogenesis | 37 | 4.17e-01 | -0.077300 | 0.699000 |
Mitochondrial iron-sulfur cluster biogenesis | 12 | 6.44e-01 | -0.077200 | 0.855000 |
Nuclear Events (kinase and transcription factor activation) | 42 | 3.88e-01 | -0.077100 | 0.673000 |
Transcriptional Regulation by TP53 | 272 | 3.00e-02 | -0.077000 | 0.261000 |
Pre-NOTCH Processing in Golgi | 15 | 6.06e-01 | 0.076900 | 0.828000 |
Glucose metabolism | 68 | 2.77e-01 | -0.076400 | 0.614000 |
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | 59 | 3.12e-01 | -0.076200 | 0.630000 |
Signaling by ERBB4 | 29 | 4.78e-01 | 0.076100 | 0.748000 |
RHOBTB GTPase Cycle | 28 | 4.87e-01 | -0.075900 | 0.751000 |
Gluconeogenesis | 23 | 5.30e-01 | -0.075700 | 0.784000 |
Polo-like kinase mediated events | 16 | 6.01e-01 | 0.075600 | 0.827000 |
Regulation of innate immune responses to cytosolic DNA | 11 | 6.64e-01 | -0.075600 | 0.863000 |
Apoptotic execution phase | 30 | 4.76e-01 | -0.075300 | 0.748000 |
Ion channel transport | 76 | 2.62e-01 | 0.074500 | 0.599000 |
Translocation of SLC2A4 (GLUT4) to the plasma membrane | 44 | 3.95e-01 | 0.074100 | 0.682000 |
Signaling by ERBB2 KD Mutants | 12 | 6.58e-01 | 0.073900 | 0.859000 |
Protein methylation | 10 | 6.86e-01 | -0.073700 | 0.877000 |
SARS-CoV-2 activates/modulates innate and adaptive immune responses | 82 | 2.50e-01 | -0.073600 | 0.583000 |
Circadian Clock | 51 | 3.64e-01 | 0.073500 | 0.661000 |
Toll Like Receptor 9 (TLR9) Cascade | 64 | 3.10e-01 | -0.073500 | 0.630000 |
Zinc transporters | 11 | 6.73e-01 | -0.073500 | 0.867000 |
Growth hormone receptor signaling | 16 | 6.11e-01 | 0.073500 | 0.831000 |
Vesicle-mediated transport | 416 | 1.12e-02 | -0.073400 | 0.161000 |
Regulation of BACH1 activity | 11 | 6.74e-01 | 0.073300 | 0.867000 |
NR1H2 and NR1H3-mediated signaling | 24 | 5.35e-01 | 0.073300 | 0.786000 |
Protein localization | 110 | 1.86e-01 | -0.073200 | 0.530000 |
Fatty acid metabolism | 90 | 2.33e-01 | 0.072900 | 0.572000 |
Peroxisomal protein import | 44 | 4.07e-01 | -0.072300 | 0.695000 |
Toll Like Receptor 3 (TLR3) Cascade | 71 | 2.94e-01 | -0.072100 | 0.616000 |
MyD88 dependent cascade initiated on endosome | 62 | 3.28e-01 | -0.071900 | 0.644000 |
Toll Like Receptor 7/8 (TLR7/8) Cascade | 62 | 3.28e-01 | -0.071900 | 0.644000 |
Signaling by PDGF | 24 | 5.43e-01 | 0.071800 | 0.791000 |
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | 18 | 5.99e-01 | 0.071700 | 0.827000 |
Regulation of PTEN gene transcription | 44 | 4.11e-01 | -0.071600 | 0.698000 |
TP53 Regulates Transcription of Cell Cycle Genes | 40 | 4.34e-01 | -0.071600 | 0.716000 |
Josephin domain DUBs | 11 | 6.83e-01 | -0.071100 | 0.875000 |
Amino acids regulate mTORC1 | 35 | 4.68e-01 | -0.070900 | 0.741000 |
Deactivation of the beta-catenin transactivating complex | 26 | 5.32e-01 | -0.070900 | 0.784000 |
PPARA activates gene expression | 79 | 2.78e-01 | 0.070700 | 0.614000 |
SARS-CoV-1 Infection | 44 | 4.19e-01 | -0.070500 | 0.701000 |
Metabolism of fat-soluble vitamins | 12 | 6.73e-01 | 0.070400 | 0.867000 |
Integration of energy metabolism | 52 | 3.82e-01 | 0.070100 | 0.669000 |
RNA polymerase II transcribes snRNA genes | 65 | 3.31e-01 | -0.069900 | 0.645000 |
DCC mediated attractive signaling | 11 | 6.89e-01 | 0.069800 | 0.877000 |
Membrane Trafficking | 409 | 1.68e-02 | -0.069700 | 0.203000 |
MAPK targets/ Nuclear events mediated by MAP kinases | 22 | 5.72e-01 | -0.069600 | 0.813000 |
MET promotes cell motility | 11 | 6.89e-01 | 0.069600 | 0.877000 |
PERK regulates gene expression | 26 | 5.42e-01 | -0.069200 | 0.791000 |
GPVI-mediated activation cascade | 21 | 5.84e-01 | -0.069000 | 0.817000 |
Switching of origins to a post-replicative state | 69 | 3.24e-01 | -0.068800 | 0.643000 |
Peptide chain elongation | 67 | 3.32e-01 | -0.068700 | 0.645000 |
Signaling by CSF3 (G-CSF) | 23 | 5.71e-01 | -0.068300 | 0.813000 |
Interactions of Rev with host cellular proteins | 32 | 5.05e-01 | -0.068200 | 0.758000 |
HIV Infection | 175 | 1.22e-01 | -0.068200 | 0.446000 |
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | 84 | 2.83e-01 | -0.067900 | 0.614000 |
Nonsense-Mediated Decay (NMD) | 84 | 2.83e-01 | -0.067900 | 0.614000 |
The role of Nef in HIV-1 replication and disease pathogenesis | 18 | 6.22e-01 | 0.067200 | 0.840000 |
RNA Polymerase III Transcription Initiation From Type 3 Promoter | 27 | 5.47e-01 | -0.067100 | 0.791000 |
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | 11 | 7.01e-01 | 0.066900 | 0.881000 |
FOXO-mediated transcription of cell cycle genes | 12 | 6.90e-01 | 0.066600 | 0.877000 |
Interferon alpha/beta signaling | 46 | 4.36e-01 | -0.066400 | 0.718000 |
Cyclin A:Cdk2-associated events at S phase entry | 70 | 3.39e-01 | -0.066200 | 0.649000 |
MyD88 cascade initiated on plasma membrane | 61 | 3.74e-01 | -0.065900 | 0.664000 |
Toll Like Receptor 10 (TLR10) Cascade | 61 | 3.74e-01 | -0.065900 | 0.664000 |
Toll Like Receptor 5 (TLR5) Cascade | 61 | 3.74e-01 | -0.065900 | 0.664000 |
Response of EIF2AK1 (HRI) to heme deficiency | 13 | 6.81e-01 | 0.065800 | 0.874000 |
Nucleotide salvage | 17 | 6.39e-01 | -0.065700 | 0.854000 |
Metabolism of steroids | 80 | 3.12e-01 | -0.065600 | 0.630000 |
RNA Polymerase I Promoter Escape | 26 | 5.63e-01 | 0.065500 | 0.804000 |
RND2 GTPase cycle | 33 | 5.15e-01 | 0.065500 | 0.769000 |
Cyclin E associated events during G1/S transition | 68 | 3.52e-01 | -0.065400 | 0.655000 |
S Phase | 127 | 2.07e-01 | -0.065100 | 0.548000 |
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | 21 | 6.06e-01 | 0.065000 | 0.828000 |
MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 64 | 3.69e-01 | -0.065000 | 0.661000 |
Toll Like Receptor 2 (TLR2) Cascade | 64 | 3.69e-01 | -0.065000 | 0.661000 |
Toll Like Receptor TLR1:TLR2 Cascade | 64 | 3.69e-01 | -0.065000 | 0.661000 |
Toll Like Receptor TLR6:TLR2 Cascade | 64 | 3.69e-01 | -0.065000 | 0.661000 |
Dual incision in TC-NER | 55 | 4.06e-01 | -0.064900 | 0.694000 |
Apoptosis | 124 | 2.15e-01 | -0.064700 | 0.551000 |
Toll-like Receptor Cascades | 96 | 2.77e-01 | -0.064400 | 0.614000 |
Metabolism of nitric oxide: NOS3 activation and regulation | 12 | 7.01e-01 | 0.064000 | 0.881000 |
Signaling by Hedgehog | 93 | 2.90e-01 | -0.063700 | 0.614000 |
Signaling by ALK | 17 | 6.51e-01 | 0.063400 | 0.856000 |
Synthesis of substrates in N-glycan biosythesis | 46 | 4.58e-01 | -0.063300 | 0.737000 |
G1/S Transition | 103 | 2.68e-01 | -0.063300 | 0.605000 |
Signaling by ALK fusions and activated point mutants | 42 | 4.79e-01 | -0.063200 | 0.748000 |
Signaling by ALK in cancer | 42 | 4.79e-01 | -0.063200 | 0.748000 |
Programmed Cell Death | 144 | 1.94e-01 | -0.063000 | 0.535000 |
Metabolism of vitamins and cofactors | 103 | 2.72e-01 | -0.062800 | 0.611000 |
Insulin receptor signalling cascade | 23 | 6.03e-01 | -0.062800 | 0.827000 |
RNA Polymerase I Transcription Termination | 24 | 5.96e-01 | 0.062600 | 0.825000 |
Nucleotide Excision Repair | 98 | 2.86e-01 | -0.062600 | 0.614000 |
Regulation of lipid metabolism by PPARalpha | 81 | 3.31e-01 | 0.062600 | 0.645000 |
B-WICH complex positively regulates rRNA expression | 27 | 5.79e-01 | 0.061700 | 0.816000 |
Regulation of KIT signaling | 10 | 7.36e-01 | 0.061500 | 0.898000 |
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | 49 | 4.58e-01 | -0.061400 | 0.737000 |
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | 19 | 6.44e-01 | 0.061200 | 0.855000 |
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 14 | 6.92e-01 | 0.061100 | 0.877000 |
PI3K Cascade | 17 | 6.63e-01 | -0.061000 | 0.863000 |
Diseases associated with glycosylation precursor biosynthesis | 15 | 6.83e-01 | -0.061000 | 0.875000 |
p75 NTR receptor-mediated signalling | 53 | 4.45e-01 | -0.060800 | 0.726000 |
Cellular Senescence | 99 | 3.00e-01 | -0.060400 | 0.619000 |
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | 20 | 6.40e-01 | 0.060400 | 0.855000 |
SUMO E3 ligases SUMOylate target proteins | 127 | 2.42e-01 | -0.060300 | 0.579000 |
Eukaryotic Translation Elongation | 70 | 3.84e-01 | -0.060300 | 0.670000 |
NGF-stimulated transcription | 25 | 6.02e-01 | -0.060200 | 0.827000 |
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 23 | 6.17e-01 | 0.060200 | 0.835000 |
RHOF GTPase cycle | 22 | 6.30e-01 | 0.059300 | 0.848000 |
Global Genome Nucleotide Excision Repair (GG-NER) | 75 | 3.76e-01 | -0.059200 | 0.664000 |
Paradoxical activation of RAF signaling by kinase inactive BRAF | 29 | 5.87e-01 | 0.058400 | 0.817000 |
Signaling by RAS mutants | 29 | 5.87e-01 | 0.058400 | 0.817000 |
Signaling by moderate kinase activity BRAF mutants | 29 | 5.87e-01 | 0.058400 | 0.817000 |
Signaling downstream of RAS mutants | 29 | 5.87e-01 | 0.058400 | 0.817000 |
RHO GTPases Activate WASPs and WAVEs | 28 | 5.95e-01 | -0.058100 | 0.825000 |
trans-Golgi Network Vesicle Budding | 50 | 4.78e-01 | -0.058100 | 0.748000 |
Recycling pathway of L1 | 15 | 6.98e-01 | 0.057900 | 0.880000 |
Eukaryotic Translation Termination | 70 | 4.03e-01 | -0.057900 | 0.691000 |
EPHB-mediated forward signaling | 25 | 6.17e-01 | -0.057800 | 0.835000 |
RHO GTPases activate PAKs | 13 | 7.19e-01 | -0.057700 | 0.897000 |
Late Phase of HIV Life Cycle | 106 | 3.08e-01 | -0.057500 | 0.630000 |
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | 18 | 6.75e-01 | -0.057100 | 0.867000 |
Integrin cell surface interactions | 22 | 6.43e-01 | 0.057100 | 0.855000 |
Nephrin family interactions | 12 | 7.33e-01 | 0.056900 | 0.898000 |
HIV Life Cycle | 117 | 2.90e-01 | -0.056800 | 0.614000 |
C-type lectin receptors (CLRs) | 92 | 3.55e-01 | -0.055900 | 0.656000 |
RHOH GTPase cycle | 25 | 6.29e-01 | 0.055800 | 0.848000 |
GPER1 signaling | 20 | 6.66e-01 | 0.055700 | 0.863000 |
SLC transporter disorders | 48 | 5.05e-01 | -0.055700 | 0.758000 |
Synthesis of PIPs at the plasma membrane | 34 | 5.77e-01 | 0.055300 | 0.816000 |
mTORC1-mediated signalling | 17 | 6.93e-01 | -0.055300 | 0.877000 |
Cellular response to starvation | 110 | 3.21e-01 | -0.054900 | 0.640000 |
Fcgamma receptor (FCGR) dependent phagocytosis | 59 | 4.67e-01 | -0.054800 | 0.741000 |
Glutamate binding, activation of AMPA receptors and synaptic plasticity | 12 | 7.45e-01 | 0.054300 | 0.898000 |
Trafficking of AMPA receptors | 12 | 7.45e-01 | 0.054300 | 0.898000 |
Cellular responses to stimuli | 513 | 3.83e-02 | -0.054200 | 0.276000 |
Negative regulation of the PI3K/AKT network | 54 | 4.92e-01 | -0.054200 | 0.751000 |
Gamma carboxylation, hypusine formation and arylsulfatase activation | 21 | 6.68e-01 | 0.054100 | 0.863000 |
Protein ubiquitination | 56 | 4.91e-01 | -0.053300 | 0.751000 |
Viral mRNA Translation | 67 | 4.53e-01 | -0.053100 | 0.734000 |
Cargo concentration in the ER | 18 | 6.97e-01 | -0.053100 | 0.879000 |
G0 and Early G1 | 24 | 6.54e-01 | 0.052900 | 0.856000 |
NOTCH3 Intracellular Domain Regulates Transcription | 15 | 7.23e-01 | 0.052800 | 0.897000 |
Cellular responses to stress | 509 | 4.46e-02 | -0.052800 | 0.305000 |
Glycosaminoglycan metabolism | 60 | 4.82e-01 | 0.052500 | 0.749000 |
Amino acid transport across the plasma membrane | 15 | 7.26e-01 | 0.052300 | 0.897000 |
DAG and IP3 signaling | 23 | 6.65e-01 | 0.052100 | 0.863000 |
Role of phospholipids in phagocytosis | 14 | 7.37e-01 | -0.051900 | 0.898000 |
Branched-chain amino acid catabolism | 20 | 6.89e-01 | -0.051800 | 0.877000 |
SUMOylation of transcription factors | 13 | 7.47e-01 | 0.051800 | 0.898000 |
Signaling by TGFB family members | 81 | 4.22e-01 | 0.051700 | 0.705000 |
Transcriptional regulation of granulopoiesis | 23 | 6.68e-01 | 0.051700 | 0.863000 |
Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 68 | 4.64e-01 | -0.051500 | 0.741000 |
Regulation of cholesterol biosynthesis by SREBP (SREBF) | 46 | 5.48e-01 | -0.051200 | 0.792000 |
Infectious disease | 591 | 3.70e-02 | -0.051100 | 0.274000 |
Sealing of the nuclear envelope (NE) by ESCRT-III | 16 | 7.25e-01 | 0.050800 | 0.897000 |
TNFR1-induced proapoptotic signaling | 12 | 7.62e-01 | -0.050600 | 0.905000 |
Rev-mediated nuclear export of HIV RNA | 31 | 6.29e-01 | -0.050200 | 0.848000 |
Sema3A PAK dependent Axon repulsion | 10 | 7.84e-01 | -0.050100 | 0.917000 |
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | 12 | 7.64e-01 | -0.050000 | 0.905000 |
Phase II - Conjugation of compounds | 41 | 5.81e-01 | 0.049900 | 0.816000 |
Selenocysteine synthesis | 68 | 4.79e-01 | -0.049800 | 0.748000 |
RHO GTPase cycle | 269 | 1.67e-01 | 0.049400 | 0.514000 |
Translation of Replicase and Assembly of the Replication Transcription Complex | 10 | 7.87e-01 | 0.049300 | 0.919000 |
Degradation of beta-catenin by the destruction complex | 64 | 4.96e-01 | -0.049300 | 0.755000 |
Estrogen-dependent gene expression | 67 | 4.91e-01 | -0.048700 | 0.751000 |
Mitotic G1 phase and G1/S transition | 118 | 3.64e-01 | -0.048500 | 0.661000 |
Aberrant regulation of mitotic cell cycle due to RB1 defects | 29 | 6.52e-01 | 0.048300 | 0.856000 |
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 15 | 7.47e-01 | 0.048200 | 0.898000 |
Prefoldin mediated transfer of substrate to CCT/TriC | 16 | 7.41e-01 | -0.047700 | 0.898000 |
Defective Intrinsic Pathway for Apoptosis | 23 | 6.92e-01 | 0.047700 | 0.877000 |
Interleukin-12 signaling | 35 | 6.30e-01 | -0.047100 | 0.848000 |
RAB GEFs exchange GTP for GDP on RABs | 52 | 5.58e-01 | -0.047100 | 0.798000 |
Response of EIF2AK4 (GCN2) to amino acid deficiency | 75 | 4.83e-01 | -0.047000 | 0.749000 |
N-glycan trimming in the ER and Calnexin/Calreticulin cycle | 31 | 6.53e-01 | -0.046700 | 0.856000 |
Translation of Structural Proteins | 27 | 6.85e-01 | -0.045200 | 0.876000 |
Energy dependent regulation of mTOR by LKB1-AMPK | 21 | 7.21e-01 | 0.045000 | 0.897000 |
PCP/CE pathway | 68 | 5.30e-01 | -0.044200 | 0.784000 |
RNA Polymerase I Transcription Initiation | 39 | 6.34e-01 | 0.044100 | 0.851000 |
Downstream signaling events of B Cell Receptor (BCR) | 66 | 5.37e-01 | -0.044000 | 0.789000 |
Downregulation of SMAD2/3:SMAD4 transcriptional activity | 23 | 7.16e-01 | -0.043800 | 0.896000 |
DAP12 interactions | 19 | 7.42e-01 | -0.043700 | 0.898000 |
EGR2 and SOX10-mediated initiation of Schwann cell myelination | 11 | 8.03e-01 | 0.043600 | 0.929000 |
Formation of tubulin folding intermediates by CCT/TriC | 13 | 7.87e-01 | -0.043200 | 0.919000 |
Regulation of signaling by CBL | 13 | 7.89e-01 | 0.042900 | 0.920000 |
IGF1R signaling cascade | 21 | 7.34e-01 | -0.042900 | 0.898000 |
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | 21 | 7.34e-01 | -0.042900 | 0.898000 |
Cyclin D associated events in G1 | 40 | 6.42e-01 | 0.042500 | 0.855000 |
G1 Phase | 40 | 6.42e-01 | 0.042500 | 0.855000 |
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | 72 | 5.34e-01 | -0.042500 | 0.786000 |
Signaling by ERBB2 TMD/JMD mutants | 10 | 8.16e-01 | 0.042400 | 0.934000 |
Interleukin-3, Interleukin-5 and GM-CSF signaling | 28 | 6.99e-01 | 0.042300 | 0.880000 |
Regulation of actin dynamics for phagocytic cup formation | 42 | 6.36e-01 | -0.042300 | 0.851000 |
Activation of gene expression by SREBF (SREBP) | 34 | 6.70e-01 | -0.042200 | 0.865000 |
Asymmetric localization of PCP proteins | 49 | 6.10e-01 | -0.042200 | 0.830000 |
Regulation of beta-cell development | 15 | 7.77e-01 | 0.042200 | 0.913000 |
Gene expression (Transcription) | 941 | 3.40e-02 | -0.042000 | 0.265000 |
TRAF6 mediated NF-kB activation | 19 | 7.55e-01 | -0.041400 | 0.903000 |
Antigen processing: Ubiquitination & Proteasome degradation | 224 | 2.90e-01 | 0.041300 | 0.614000 |
Transcriptional regulation by RUNX2 | 78 | 5.30e-01 | -0.041200 | 0.784000 |
ERKs are inactivated | 11 | 8.14e-01 | 0.041000 | 0.933000 |
Transcription of E2F targets under negative control by DREAM complex | 17 | 7.71e-01 | 0.040800 | 0.909000 |
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 41 | 6.54e-01 | 0.040500 | 0.856000 |
Constitutive Signaling by NOTCH1 PEST Domain Mutants | 41 | 6.54e-01 | 0.040500 | 0.856000 |
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 41 | 6.54e-01 | 0.040500 | 0.856000 |
Signaling by NOTCH1 PEST Domain Mutants in Cancer | 41 | 6.54e-01 | 0.040500 | 0.856000 |
Signaling by NOTCH1 in Cancer | 41 | 6.54e-01 | 0.040500 | 0.856000 |
ATF4 activates genes in response to endoplasmic reticulum stress | 23 | 7.40e-01 | -0.040000 | 0.898000 |
Signaling by ERBB2 ECD mutants | 10 | 8.27e-01 | 0.039900 | 0.935000 |
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | 19 | 7.64e-01 | 0.039800 | 0.905000 |
RNA Polymerase III Chain Elongation | 17 | 7.77e-01 | -0.039700 | 0.913000 |
Transcriptional regulation by RUNX1 | 118 | 4.68e-01 | 0.038800 | 0.741000 |
SUMOylation | 132 | 4.44e-01 | -0.038700 | 0.726000 |
Cytoprotection by HMOX1 | 42 | 6.65e-01 | 0.038700 | 0.863000 |
CLEC7A (Dectin-1) induces NFAT activation | 11 | 8.24e-01 | -0.038600 | 0.935000 |
Cytokine Signaling in Immune system | 392 | 1.96e-01 | -0.038500 | 0.537000 |
Synthesis of active ubiquitin: roles of E1 and E2 enzymes | 25 | 7.40e-01 | -0.038300 | 0.898000 |
APC-Cdc20 mediated degradation of Nek2A | 21 | 7.62e-01 | -0.038200 | 0.905000 |
Amyloid fiber formation | 25 | 7.42e-01 | -0.038000 | 0.898000 |
CD28 dependent PI3K/Akt signaling | 18 | 7.82e-01 | -0.037700 | 0.916000 |
FCERI mediated Ca+2 mobilization | 22 | 7.60e-01 | 0.037600 | 0.905000 |
Disease | 1022 | 5.03e-02 | -0.037300 | 0.321000 |
Association of TriC/CCT with target proteins during biosynthesis | 29 | 7.28e-01 | -0.037300 | 0.897000 |
RNA Polymerase II Transcription | 835 | 7.47e-02 | -0.037200 | 0.368000 |
Signaling by WNT | 165 | 4.13e-01 | 0.037100 | 0.699000 |
Sema4D induced cell migration and growth-cone collapse | 11 | 8.33e-01 | 0.036700 | 0.938000 |
Glyoxylate metabolism and glycine degradation | 19 | 7.82e-01 | -0.036700 | 0.916000 |
Macroautophagy | 85 | 5.62e-01 | 0.036400 | 0.804000 |
Cleavage of the damaged purine | 10 | 8.42e-01 | 0.036300 | 0.938000 |
Depurination | 10 | 8.42e-01 | 0.036300 | 0.938000 |
Recognition and association of DNA glycosylase with site containing an affected purine | 10 | 8.42e-01 | 0.036300 | 0.938000 |
Diseases of signal transduction by growth factor receptors and second messengers | 284 | 2.97e-01 | -0.036300 | 0.617000 |
Formation of HIV-1 elongation complex containing HIV-1 Tat | 31 | 7.27e-01 | -0.036300 | 0.897000 |
HIV Transcription Elongation | 31 | 7.27e-01 | -0.036300 | 0.897000 |
Tat-mediated elongation of the HIV-1 transcript | 31 | 7.27e-01 | -0.036300 | 0.897000 |
Autophagy | 93 | 5.47e-01 | 0.036200 | 0.791000 |
Platelet sensitization by LDL | 13 | 8.22e-01 | 0.036100 | 0.935000 |
Nuclear Receptor transcription pathway | 26 | 7.51e-01 | -0.036000 | 0.900000 |
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | 14 | 8.16e-01 | 0.036000 | 0.934000 |
HDACs deacetylate histones | 28 | 7.43e-01 | -0.035800 | 0.898000 |
Mitochondrial translation | 84 | 5.72e-01 | -0.035700 | 0.813000 |
PIWI-interacting RNA (piRNA) biogenesis | 15 | 8.11e-01 | -0.035600 | 0.933000 |
RNA Pol II CTD phosphorylation and interaction with CE | 23 | 7.68e-01 | -0.035500 | 0.907000 |
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 23 | 7.68e-01 | -0.035500 | 0.907000 |
Adaptive Immune System | 439 | 2.08e-01 | 0.035500 | 0.550000 |
G alpha (12/13) signalling events | 33 | 7.25e-01 | 0.035500 | 0.897000 |
Nuclear events stimulated by ALK signaling in cancer | 13 | 8.25e-01 | 0.035400 | 0.935000 |
Inactivation, recovery and regulation of the phototransduction cascade | 16 | 8.08e-01 | 0.035200 | 0.931000 |
The phototransduction cascade | 16 | 8.08e-01 | 0.035200 | 0.931000 |
Metabolism of amino acids and derivatives | 214 | 3.79e-01 | -0.035100 | 0.666000 |
Signalling to ERKs | 25 | 7.64e-01 | 0.034700 | 0.905000 |
Frs2-mediated activation | 11 | 8.42e-01 | -0.034700 | 0.938000 |
FCGR3A-mediated phagocytosis | 40 | 7.06e-01 | -0.034500 | 0.884000 |
Leishmania phagocytosis | 40 | 7.06e-01 | -0.034500 | 0.884000 |
Parasite infection | 40 | 7.06e-01 | -0.034500 | 0.884000 |
Signal Transduction | 1254 | 5.04e-02 | 0.034100 | 0.321000 |
Cargo trafficking to the periciliary membrane | 37 | 7.20e-01 | -0.034000 | 0.897000 |
Membrane binding and targetting of GAG proteins | 11 | 8.45e-01 | -0.034000 | 0.938000 |
Synthesis And Processing Of GAG, GAGPOL Polyproteins | 11 | 8.45e-01 | -0.034000 | 0.938000 |
RHOC GTPase cycle | 45 | 6.95e-01 | 0.033800 | 0.879000 |
Endosomal Sorting Complex Required For Transport (ESCRT) | 25 | 7.72e-01 | -0.033500 | 0.910000 |
Platelet activation, signaling and aggregation | 120 | 5.29e-01 | -0.033400 | 0.784000 |
Positive epigenetic regulation of rRNA expression | 40 | 7.19e-01 | 0.032900 | 0.897000 |
Diseases of programmed cell death | 37 | 7.29e-01 | -0.032900 | 0.897000 |
G-protein mediated events | 27 | 7.68e-01 | -0.032900 | 0.907000 |
Insulin receptor recycling | 17 | 8.16e-01 | 0.032700 | 0.934000 |
Sialic acid metabolism | 22 | 7.92e-01 | 0.032500 | 0.922000 |
Signaling by Receptor Tyrosine Kinases | 279 | 3.59e-01 | 0.032100 | 0.661000 |
Hemostasis | 279 | 3.61e-01 | 0.032100 | 0.661000 |
Epigenetic regulation of gene expression | 73 | 6.38e-01 | 0.031900 | 0.853000 |
Metabolism of lipids | 401 | 2.79e-01 | 0.031900 | 0.614000 |
TCR signaling | 77 | 6.36e-01 | -0.031300 | 0.851000 |
Constitutive Signaling by EGFRvIII | 10 | 8.65e-01 | 0.031200 | 0.948000 |
Signaling by EGFRvIII in Cancer | 10 | 8.65e-01 | 0.031200 | 0.948000 |
Fc epsilon receptor (FCERI) signaling | 100 | 5.92e-01 | -0.031100 | 0.823000 |
MAP2K and MAPK activation | 22 | 8.03e-01 | 0.030700 | 0.929000 |
Signaling by high-kinase activity BRAF mutants | 22 | 8.03e-01 | 0.030700 | 0.929000 |
Negative epigenetic regulation of rRNA expression | 43 | 7.29e-01 | 0.030600 | 0.897000 |
EPH-ephrin mediated repulsion of cells | 24 | 7.96e-01 | 0.030500 | 0.926000 |
Semaphorin interactions | 34 | 7.59e-01 | 0.030500 | 0.905000 |
TCF dependent signaling in response to WNT | 112 | 5.79e-01 | 0.030400 | 0.816000 |
Signaling by Interleukins | 248 | 4.16e-01 | -0.030200 | 0.699000 |
ECM proteoglycans | 10 | 8.70e-01 | -0.029900 | 0.949000 |
Chromatin modifying enzymes | 139 | 5.46e-01 | -0.029800 | 0.791000 |
Chromatin organization | 139 | 5.46e-01 | -0.029800 | 0.791000 |
CD28 co-stimulation | 27 | 7.90e-01 | 0.029700 | 0.921000 |
Interleukin-17 signaling | 49 | 7.22e-01 | -0.029500 | 0.897000 |
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 15 | 8.45e-01 | 0.029200 | 0.938000 |
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 15 | 8.45e-01 | 0.029200 | 0.938000 |
Formation of HIV elongation complex in the absence of HIV Tat | 32 | 7.76e-01 | -0.029100 | 0.913000 |
RNA Polymerase I Promoter Clearance | 43 | 7.42e-01 | 0.029100 | 0.898000 |
RNA Polymerase I Transcription | 43 | 7.42e-01 | 0.029100 | 0.898000 |
Keratan sulfate/keratin metabolism | 18 | 8.33e-01 | 0.028800 | 0.938000 |
Signaling by the B Cell Receptor (BCR) | 84 | 6.52e-01 | -0.028500 | 0.856000 |
Sphingolipid de novo biosynthesis | 18 | 8.38e-01 | -0.027900 | 0.938000 |
Transport of small molecules | 320 | 3.96e-01 | 0.027800 | 0.682000 |
Signaling by FGFR2 in disease | 23 | 8.17e-01 | -0.027800 | 0.934000 |
Phosphorylation of the APC/C | 15 | 8.53e-01 | -0.027600 | 0.945000 |
Neutrophil degranulation | 275 | 4.34e-01 | -0.027600 | 0.716000 |
Metabolism of proteins | 1162 | 1.27e-01 | -0.027600 | 0.452000 |
Signaling by Nuclear Receptors | 145 | 5.74e-01 | 0.027200 | 0.814000 |
SARS-CoV-2 targets host intracellular signalling and regulatory pathways | 11 | 8.77e-01 | 0.026900 | 0.950000 |
VEGFR2 mediated cell proliferation | 16 | 8.54e-01 | 0.026600 | 0.946000 |
Signaling by NOTCH3 | 30 | 8.02e-01 | -0.026400 | 0.929000 |
Transcriptional regulation of white adipocyte differentiation | 55 | 7.35e-01 | 0.026400 | 0.898000 |
Selenoamino acid metabolism | 76 | 6.92e-01 | -0.026300 | 0.877000 |
Neddylation | 175 | 5.56e-01 | -0.025900 | 0.797000 |
Interleukin-6 family signaling | 13 | 8.72e-01 | 0.025800 | 0.950000 |
The NLRP3 inflammasome | 12 | 8.78e-01 | 0.025700 | 0.950000 |
mRNA Capping | 25 | 8.25e-01 | -0.025600 | 0.935000 |
Hedgehog ‘on’ state | 60 | 7.32e-01 | -0.025600 | 0.898000 |
Mitochondrial Fatty Acid Beta-Oxidation | 25 | 8.26e-01 | 0.025400 | 0.935000 |
Generic Transcription Pathway | 746 | 2.48e-01 | -0.025400 | 0.583000 |
Notch-HLH transcription pathway | 21 | 8.41e-01 | 0.025300 | 0.938000 |
Signaling by VEGF | 72 | 7.15e-01 | 0.024900 | 0.895000 |
Transcriptional Regulation by MECP2 | 27 | 8.23e-01 | 0.024900 | 0.935000 |
Initiation of Nuclear Envelope (NE) Reformation | 17 | 8.62e-01 | -0.024300 | 0.948000 |
Diseases of metabolism | 120 | 6.48e-01 | 0.024200 | 0.856000 |
Signaling by NOTCH | 127 | 6.52e-01 | -0.023300 | 0.856000 |
RHOB GTPase cycle | 40 | 8.01e-01 | -0.023000 | 0.929000 |
FCGR3A-mediated IL10 synthesis | 19 | 8.63e-01 | -0.022900 | 0.948000 |
VEGFA-VEGFR2 Pathway | 70 | 7.42e-01 | 0.022800 | 0.898000 |
MTOR signalling | 32 | 8.23e-01 | 0.022800 | 0.935000 |
Glycogen storage diseases | 10 | 9.01e-01 | 0.022800 | 0.969000 |
Sulfur amino acid metabolism | 17 | 8.73e-01 | -0.022400 | 0.950000 |
Signaling by Rho GTPases | 407 | 4.46e-01 | -0.022300 | 0.727000 |
Iron uptake and transport | 36 | 8.22e-01 | -0.021700 | 0.935000 |
Budding and maturation of HIV virion | 22 | 8.64e-01 | 0.021100 | 0.948000 |
Formation of the Early Elongation Complex | 25 | 8.57e-01 | 0.020900 | 0.946000 |
Formation of the HIV-1 Early Elongation Complex | 25 | 8.57e-01 | 0.020900 | 0.946000 |
TNFR2 non-canonical NF-kB pathway | 62 | 7.78e-01 | -0.020800 | 0.913000 |
Transferrin endocytosis and recycling | 19 | 8.76e-01 | 0.020700 | 0.950000 |
Signaling by FGFR in disease | 38 | 8.27e-01 | 0.020500 | 0.935000 |
Mitochondrial translation termination | 78 | 7.56e-01 | -0.020400 | 0.904000 |
Platelet degranulation | 45 | 8.13e-01 | 0.020400 | 0.933000 |
Signaling by Non-Receptor Tyrosine Kinases | 33 | 8.43e-01 | -0.019900 | 0.938000 |
Signaling by PTK6 | 33 | 8.43e-01 | -0.019900 | 0.938000 |
RNA Polymerase III Transcription Termination | 20 | 8.80e-01 | -0.019500 | 0.951000 |
EPH-Ephrin signaling | 53 | 8.06e-01 | -0.019500 | 0.931000 |
Signaling by NTRKs | 86 | 7.58e-01 | 0.019300 | 0.905000 |
Axon guidance | 275 | 6.00e-01 | -0.018500 | 0.827000 |
NoRC negatively regulates rRNA expression | 41 | 8.39e-01 | 0.018400 | 0.938000 |
Diseases of glycosylation | 65 | 7.99e-01 | 0.018300 | 0.928000 |
Immune System | 1056 | 3.35e-01 | 0.018100 | 0.645000 |
Metabolism of carbohydrates | 171 | 6.92e-01 | -0.017600 | 0.877000 |
Leishmania infection | 103 | 7.64e-01 | 0.017200 | 0.905000 |
Glycerophospholipid biosynthesis | 66 | 8.11e-01 | 0.017100 | 0.933000 |
Phospholipid metabolism | 123 | 7.45e-01 | 0.017000 | 0.898000 |
Keratan sulfate biosynthesis | 14 | 9.15e-01 | 0.016400 | 0.974000 |
Metabolism of nucleotides | 64 | 8.22e-01 | -0.016300 | 0.935000 |
Cell death signalling via NRAGE, NRIF and NADE | 39 | 8.61e-01 | -0.016200 | 0.948000 |
Chaperonin-mediated protein folding | 51 | 8.42e-01 | 0.016100 | 0.938000 |
Signaling by Rho GTPases, Miro GTPases and RHOBTB3 | 419 | 5.78e-01 | -0.016000 | 0.816000 |
Transcriptional Regulation by VENTX | 24 | 8.92e-01 | -0.016000 | 0.961000 |
Cellular response to chemical stress | 137 | 7.50e-01 | 0.015800 | 0.900000 |
Synthesis of PIPs at the Golgi membrane | 12 | 9.25e-01 | -0.015600 | 0.975000 |
Gastrin-CREB signalling pathway via PKC and MAPK | 11 | 9.29e-01 | -0.015600 | 0.975000 |
KEAP1-NFE2L2 pathway | 81 | 8.09e-01 | -0.015500 | 0.932000 |
Downstream signaling of activated FGFR1 | 11 | 9.31e-01 | -0.015100 | 0.975000 |
Downstream signaling of activated FGFR2 | 11 | 9.31e-01 | -0.015100 | 0.975000 |
Downstream signaling of activated FGFR3 | 11 | 9.31e-01 | -0.015100 | 0.975000 |
Downstream signaling of activated FGFR4 | 11 | 9.31e-01 | -0.015100 | 0.975000 |
Nervous system development | 285 | 6.68e-01 | -0.014900 | 0.863000 |
Post-chaperonin tubulin folding pathway | 12 | 9.30e-01 | 0.014700 | 0.975000 |
Golgi Associated Vesicle Biogenesis | 37 | 8.78e-01 | -0.014600 | 0.950000 |
Nuclear events mediated by NFE2L2 | 63 | 8.42e-01 | -0.014500 | 0.938000 |
Glycosphingolipid metabolism | 25 | 9.02e-01 | 0.014200 | 0.970000 |
NCAM signaling for neurite out-growth | 21 | 9.11e-01 | 0.014000 | 0.973000 |
MAPK family signaling cascades | 176 | 7.51e-01 | -0.013900 | 0.900000 |
Selective autophagy | 48 | 8.68e-01 | -0.013900 | 0.948000 |
Apoptotic cleavage of cellular proteins | 22 | 9.11e-01 | -0.013800 | 0.973000 |
Post-translational protein modification | 855 | 5.05e-01 | -0.013800 | 0.758000 |
Signaling by Insulin receptor | 39 | 8.83e-01 | -0.013700 | 0.953000 |
Developmental Biology | 429 | 6.32e-01 | -0.013600 | 0.850000 |
Activation of BAD and translocation to mitochondria | 14 | 9.30e-01 | 0.013500 | 0.975000 |
Negative regulation of MAPK pathway | 35 | 8.91e-01 | 0.013400 | 0.961000 |
Signaling by NTRK1 (TRKA) | 79 | 8.38e-01 | 0.013400 | 0.938000 |
Diseases of mitotic cell cycle | 30 | 8.99e-01 | 0.013300 | 0.968000 |
Mitochondrial biogenesis | 52 | 8.68e-01 | -0.013300 | 0.948000 |
O-linked glycosylation of mucins | 24 | 9.11e-01 | 0.013300 | 0.973000 |
Glycolysis | 54 | 8.68e-01 | -0.013100 | 0.948000 |
Protein folding | 57 | 8.65e-01 | 0.013000 | 0.948000 |
PI Metabolism | 58 | 8.65e-01 | 0.013000 | 0.948000 |
Interleukin-4 and Interleukin-13 signaling | 48 | 8.77e-01 | -0.012900 | 0.950000 |
Mitochondrial translation initiation | 79 | 8.46e-01 | -0.012700 | 0.938000 |
Inactivation of CSF3 (G-CSF) signaling | 18 | 9.26e-01 | -0.012700 | 0.975000 |
Activation of the pre-replicative complex | 23 | 9.17e-01 | 0.012600 | 0.974000 |
Class I MHC mediated antigen processing & presentation | 265 | 7.35e-01 | 0.012200 | 0.898000 |
DAP12 signaling | 17 | 9.31e-01 | -0.012100 | 0.975000 |
Metal ion SLC transporters | 15 | 9.35e-01 | -0.012100 | 0.979000 |
Negative regulators of DDX58/IFIH1 signaling | 32 | 9.06e-01 | 0.012100 | 0.972000 |
Signaling by TGF-beta Receptor Complex | 68 | 8.65e-01 | 0.012000 | 0.948000 |
Nuclear Envelope (NE) Reassembly | 56 | 8.81e-01 | 0.011600 | 0.951000 |
Regulation of insulin secretion | 33 | 9.09e-01 | 0.011500 | 0.973000 |
RHOU GTPase cycle | 28 | 9.16e-01 | -0.011500 | 0.974000 |
Regulation of TP53 Activity through Acetylation | 26 | 9.20e-01 | -0.011400 | 0.975000 |
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | 15 | 9.41e-01 | -0.011000 | 0.983000 |
Post-translational modification: synthesis of GPI-anchored proteins | 29 | 9.19e-01 | -0.011000 | 0.974000 |
MAPK1/MAPK3 signaling | 152 | 8.19e-01 | -0.010800 | 0.935000 |
Transcriptional activation of mitochondrial biogenesis | 39 | 9.09e-01 | -0.010600 | 0.973000 |
Signaling by NTRK2 (TRKB) | 15 | 9.47e-01 | 0.009960 | 0.987000 |
Factors involved in megakaryocyte development and platelet production | 82 | 8.77e-01 | -0.009940 | 0.950000 |
Interleukin-12 family signaling | 41 | 9.14e-01 | -0.009750 | 0.974000 |
RUNX3 regulates NOTCH signaling | 11 | 9.57e-01 | -0.009500 | 0.988000 |
Prolonged ERK activation events | 13 | 9.53e-01 | -0.009450 | 0.988000 |
Synthesis of bile acids and bile salts | 12 | 9.55e-01 | 0.009320 | 0.988000 |
ESR-mediated signaling | 110 | 8.67e-01 | -0.009240 | 0.948000 |
Signaling by MET | 37 | 9.23e-01 | -0.009180 | 0.975000 |
Metabolism | 1153 | 6.17e-01 | -0.009060 | 0.835000 |
Cytosolic sensors of pathogen-associated DNA | 52 | 9.12e-01 | -0.008830 | 0.973000 |
GAB1 signalosome | 10 | 9.62e-01 | 0.008720 | 0.990000 |
PLC beta mediated events | 24 | 9.42e-01 | -0.008600 | 0.983000 |
Effects of PIP2 hydrolysis | 18 | 9.51e-01 | -0.008410 | 0.988000 |
Formation of TC-NER Pre-Incision Complex | 45 | 9.23e-01 | -0.008320 | 0.975000 |
Formation of the beta-catenin:TCF transactivating complex | 22 | 9.47e-01 | 0.008180 | 0.987000 |
Deadenylation of mRNA | 22 | 9.48e-01 | -0.008000 | 0.987000 |
Unwinding of DNA | 10 | 9.65e-01 | 0.007950 | 0.991000 |
Innate Immune System | 563 | 7.52e-01 | -0.007920 | 0.901000 |
Extra-nuclear estrogen signaling | 47 | 9.27e-01 | 0.007780 | 0.975000 |
Interleukin-6 signaling | 10 | 9.66e-01 | 0.007680 | 0.991000 |
Stimuli-sensing channels | 35 | 9.38e-01 | 0.007550 | 0.981000 |
IRS-related events triggered by IGF1R | 20 | 9.54e-01 | -0.007380 | 0.988000 |
Metabolism of porphyrins | 15 | 9.62e-01 | 0.007090 | 0.990000 |
IRS-mediated signalling | 19 | 9.59e-01 | -0.006800 | 0.989000 |
E2F mediated regulation of DNA replication | 12 | 9.70e-01 | 0.006300 | 0.992000 |
Transcriptional Regulation by E2F6 | 26 | 9.56e-01 | -0.006260 | 0.988000 |
Ub-specific processing proteases | 128 | 9.06e-01 | 0.006030 | 0.972000 |
Senescence-Associated Secretory Phenotype (SASP) | 39 | 9.49e-01 | -0.005970 | 0.987000 |
Pyruvate metabolism and Citric Acid (TCA) cycle | 38 | 9.54e-01 | -0.005460 | 0.988000 |
SHC1 events in ERBB2 signaling | 11 | 9.75e-01 | 0.005430 | 0.994000 |
Assembly Of The HIV Virion | 13 | 9.73e-01 | -0.005320 | 0.994000 |
Response to elevated platelet cytosolic Ca2+ | 49 | 9.55e-01 | 0.004710 | 0.988000 |
Signal amplification | 16 | 9.75e-01 | -0.004540 | 0.994000 |
Deubiquitination | 189 | 9.17e-01 | -0.004420 | 0.974000 |
Glutathione conjugation | 18 | 9.75e-01 | -0.004340 | 0.994000 |
FLT3 Signaling | 27 | 9.69e-01 | -0.004310 | 0.992000 |
RHO GTPases Activate NADPH Oxidases | 14 | 9.80e-01 | 0.003920 | 0.997000 |
Potential therapeutics for SARS | 63 | 9.58e-01 | -0.003800 | 0.989000 |
Signaling by ERBB2 in Cancer | 13 | 9.82e-01 | -0.003550 | 0.998000 |
Sphingolipid metabolism | 43 | 9.69e-01 | -0.003440 | 0.992000 |
RHOA GTPase cycle | 83 | 9.65e-01 | -0.002780 | 0.991000 |
Beta-catenin independent WNT signaling | 97 | 9.64e-01 | 0.002670 | 0.991000 |
Elastic fibre formation | 13 | 9.87e-01 | 0.002630 | 0.998000 |
Inflammasomes | 16 | 9.86e-01 | 0.002510 | 0.998000 |
DDX58/IFIH1-mediated induction of interferon-alpha/beta | 55 | 9.76e-01 | -0.002380 | 0.994000 |
Inositol phosphate metabolism | 29 | 9.85e-01 | -0.002050 | 0.998000 |
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | 15 | 9.90e-01 | 0.001860 | 0.998000 |
Pre-NOTCH Expression and Processing | 41 | 9.86e-01 | -0.001610 | 0.998000 |
Mitochondrial translation elongation | 79 | 9.83e-01 | -0.001400 | 0.998000 |
Signalling to RAS | 12 | 9.95e-01 | 0.001090 | 0.998000 |
NRAGE signals death through JNK | 24 | 9.94e-01 | -0.000925 | 0.998000 |
RAF/MAP kinase cascade | 147 | 9.85e-01 | -0.000900 | 0.998000 |
Sema4D in semaphorin signaling | 13 | 9.96e-01 | 0.000838 | 0.998000 |
Late endosomal microautophagy | 21 | 9.95e-01 | -0.000834 | 0.998000 |
Interferon gamma signaling | 50 | 9.93e-01 | 0.000764 | 0.998000 |
Synthesis of PC | 21 | 9.95e-01 | 0.000723 | 0.998000 |
Interleukin-37 signaling | 15 | 9.97e-01 | 0.000604 | 0.998000 |
Postmitotic nuclear pore complex (NPC) reformation | 25 | 9.97e-01 | -0.000477 | 0.998000 |
SUMOylation of chromatin organization proteins | 45 | 9.96e-01 | -0.000427 | 0.998000 |
Activated NOTCH1 Transmits Signal to the Nucleus | 19 | 9.98e-01 | -0.000407 | 0.998000 |
BMAL1:CLOCK,NPAS2 activates circadian gene expression | 15 | 9.98e-01 | -0.000373 | 0.998000 |
MHC class II antigen presentation | 66 | 9.98e-01 | -0.000212 | 0.998000 |
Purine catabolism
723 | |
---|---|
set | Purine catabolism |
setSize | 10 |
pANOVA | 0.00917 |
s.dist | -0.476 |
p.adjustANOVA | 0.158 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NT5C | -8902.0 |
PNP | -8273.0 |
NUDT15 | -8164.0 |
NUDT16 | -7893.0 |
ITPA | -7113.0 |
NT5C2 | -6272.0 |
NUDT9 | -5480.0 |
NUDT5 | -4949.0 |
NUDT1 | -3852.5 |
NUDT18 | -2807.0 |
GeneID | Gene Rank |
---|---|
NT5C | -8902.0 |
PNP | -8273.0 |
NUDT15 | -8164.0 |
NUDT16 | -7893.0 |
ITPA | -7113.0 |
NT5C2 | -6272.0 |
NUDT9 | -5480.0 |
NUDT5 | -4949.0 |
NUDT1 | -3852.5 |
NUDT18 | -2807.0 |
Meiotic recombination
519 | |
---|---|
set | Meiotic recombination |
setSize | 19 |
pANOVA | 0.000838 |
s.dist | -0.443 |
p.adjustANOVA | 0.0515 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
MSH5 | -8789.0 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
PSMC3IP | -8067.0 |
MND1 | -7741.0 |
BLM | -7501.0 |
TOP3A | -7020.5 |
RPA3 | -6328.0 |
CDK4 | -6073.0 |
MLH3 | -5573.0 |
DMC1 | -4318.0 |
H2AFX | -3494.0 |
RPA1 | -3377.5 |
CDK2 | -3323.5 |
RAD50 | -1967.0 |
NBN | -1658.0 |
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
MSH5 | -8789.0 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
PSMC3IP | -8067.0 |
MND1 | -7741.0 |
BLM | -7501.0 |
TOP3A | -7020.5 |
RPA3 | -6328.0 |
CDK4 | -6073.0 |
MLH3 | -5573.0 |
DMC1 | -4318.0 |
H2AFX | -3494.0 |
RPA1 | -3377.5 |
CDK2 | -3323.5 |
RAD50 | -1967.0 |
NBN | -1658.0 |
p75NTR signals via NF-kB
1160 | |
---|---|
set | p75NTR signals via NF-kB |
setSize | 11 |
pANOVA | 0.0118 |
s.dist | -0.439 |
p.adjustANOVA | 0.164 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
NFKBIA | -8516.0 |
MYD88 | -8048.0 |
IKBKB | -7351.0 |
TRAF6 | -7283.0 |
UBB | -7240.0 |
SQSTM1 | -6839.0 |
PRKCI | -5240.0 |
UBA52 | -634.0 |
RELA | 353.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
NFKBIA | -8516.0 |
MYD88 | -8048.0 |
IKBKB | -7351.0 |
TRAF6 | -7283.0 |
UBB | -7240.0 |
SQSTM1 | -6839.0 |
PRKCI | -5240.0 |
UBA52 | -634.0 |
RELA | 353.0 |
Negative regulation of NMDA receptor-mediated neuronal transmission
605 | |
---|---|
set | Negative regulation of NMDA receptor-mediated neuronal transmission |
setSize | 11 |
pANOVA | 0.0126 |
s.dist | 0.435 |
p.adjustANOVA | 0.173 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CAMK1 | 855.0 |
DLG1 | 633.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
CAMK4 | -481.0 |
CALM1 | -817.0 |
PPM1F | -2994.0 |
DLG4 | -3314.0 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
GeneID | Gene Rank |
---|---|
CAMK1 | 855.0 |
DLG1 | 633.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
CAMK4 | -481.0 |
CALM1 | -817.0 |
PPM1F | -2994.0 |
DLG4 | -3314.0 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
Signaling by Leptin
961 | |
---|---|
set | Signaling by Leptin |
setSize | 10 |
pANOVA | 0.0182 |
s.dist | 0.431 |
p.adjustANOVA | 0.209 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IRS2 | 875.0 |
SOCS3 | 652.0 |
JAK2 | 0.5 |
LEPR | -443.5 |
STAT5A | -929.0 |
STAT5B | -1073.0 |
SH2B1 | -1515.0 |
STAT3 | -2825.0 |
PTPN11 | -6287.0 |
IRS1 | -7564.0 |
GeneID | Gene Rank |
---|---|
IRS2 | 875.0 |
SOCS3 | 652.0 |
JAK2 | 0.5 |
LEPR | -443.5 |
STAT5A | -929.0 |
STAT5B | -1073.0 |
SH2B1 | -1515.0 |
STAT3 | -2825.0 |
PTPN11 | -6287.0 |
IRS1 | -7564.0 |
Signaling by BMP
929 | |
---|---|
set | Signaling by BMP |
setSize | 14 |
pANOVA | 0.00553 |
s.dist | 0.428 |
p.adjustANOVA | 0.13 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SMURF2 | 883.0 |
ACVR2A | 0.5 |
BMPR2 | 0.5 |
BMPR1A | 0.5 |
SMAD7 | 0.5 |
ACVR2B | -908.5 |
SKI | -1033.0 |
SMAD1 | -1553.0 |
UBE2D3 | -1554.5 |
SMURF1 | -2491.0 |
UBE2D1 | -4090.0 |
SMAD6 | -4422.0 |
SMAD5 | -5681.5 |
ZFYVE16 | -6129.0 |
GeneID | Gene Rank |
---|---|
SMURF2 | 883.0 |
ACVR2A | 0.5 |
BMPR2 | 0.5 |
BMPR1A | 0.5 |
SMAD7 | 0.5 |
ACVR2B | -908.5 |
SKI | -1033.0 |
SMAD1 | -1553.0 |
UBE2D3 | -1554.5 |
SMURF1 | -2491.0 |
UBE2D1 | -4090.0 |
SMAD6 | -4422.0 |
SMAD5 | -5681.5 |
ZFYVE16 | -6129.0 |
IKK complex recruitment mediated by RIP1
417 | |
---|---|
set | IKK complex recruitment mediated by RIP1 |
setSize | 17 |
pANOVA | 0.00663 |
s.dist | -0.38 |
p.adjustANOVA | 0.138 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
CHUK | -8055.0 |
RIPK3 | -7627.0 |
IKBKB | -7351.0 |
TRAF6 | -7283.0 |
UBB | -7240.0 |
UBE2D2 | -6859.0 |
TICAM1 | -6700.0 |
SARM1 | -6652.0 |
BIRC2 | -5780.0 |
UBE2V1 | -5429.0 |
UBE2D1 | -4090.0 |
UBE2N | -4053.0 |
BIRC3 | -3734.0 |
UBE2D3 | -1554.5 |
UBA52 | -634.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
CHUK | -8055.0 |
RIPK3 | -7627.0 |
IKBKB | -7351.0 |
TRAF6 | -7283.0 |
UBB | -7240.0 |
UBE2D2 | -6859.0 |
TICAM1 | -6700.0 |
SARM1 | -6652.0 |
BIRC2 | -5780.0 |
UBE2V1 | -5429.0 |
UBE2D1 | -4090.0 |
UBE2N | -4053.0 |
BIRC3 | -3734.0 |
UBE2D3 | -1554.5 |
UBA52 | -634.0 |
Ras activation upon Ca2+ influx through NMDA receptor
805 | |
---|---|
set | Ras activation upon Ca2+ influx through NMDA receptor |
setSize | 10 |
pANOVA | 0.0396 |
s.dist | 0.376 |
p.adjustANOVA | 0.279 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DLG1 | 633.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
HRAS | -508.0 |
CALM1 | -817.0 |
KRAS | -3095.0 |
DLG4 | -3314.0 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
GeneID | Gene Rank |
---|---|
DLG1 | 633.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
HRAS | -508.0 |
CALM1 | -817.0 |
KRAS | -3095.0 |
DLG4 | -3314.0 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
Potassium Channels
701 | |
---|---|
set | Potassium Channels |
setSize | 23 |
pANOVA | 0.00189 |
s.dist | 0.374 |
p.adjustANOVA | 0.0919 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
KCNQ1 | 848.5 |
GNG2 | 620.0 |
KCNA3 | 592.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
KCNC4 | 0.5 |
KCNG3 | 0.5 |
GNGT2 | 0.5 |
KCNQ5 | -497.0 |
KCNK6 | -664.0 |
KCNH4 | -876.0 |
KCNMB4 | -1430.0 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
KCNQ4 | -4242.0 |
KCNAB2 | -4418.0 |
GNB5 | -4674.0 |
KCNJ11 | -4765.0 |
GNG3 | -5234.0 |
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
KCNQ1 | 848.5 |
GNG2 | 620.0 |
KCNA3 | 592.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
KCNC4 | 0.5 |
KCNG3 | 0.5 |
GNGT2 | 0.5 |
KCNQ5 | -497.0 |
KCNK6 | -664.0 |
KCNH4 | -876.0 |
KCNMB4 | -1430.0 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
KCNQ4 | -4242.0 |
KCNAB2 | -4418.0 |
GNB5 | -4674.0 |
KCNJ11 | -4765.0 |
GNG3 | -5234.0 |
KCNN4 | -5352.0 |
HCN3 | -5548.0 |
GNB2 | -8449.0 |
SARS-CoV-2 modulates autophagy
879 | |
---|---|
set | SARS-CoV-2 modulates autophagy |
setSize | 10 |
pANOVA | 0.0467 |
s.dist | -0.363 |
p.adjustANOVA | 0.313 |
Top enriched genes
GeneID | Gene Rank |
---|---|
VPS39 | -8119.0 |
UVRAG | -7478.0 |
VPS18 | -7033.0 |
VPS16 | -6035.5 |
VPS41 | -5652.0 |
VPS45 | -5497.0 |
VPS33A | -5185.0 |
VPS11 | -5056.0 |
MAP1LC3B | -4785.0 |
TUFM | -3334.0 |
GeneID | Gene Rank |
---|---|
VPS39 | -8119.0 |
UVRAG | -7478.0 |
VPS18 | -7033.0 |
VPS16 | -6035.5 |
VPS41 | -5652.0 |
VPS45 | -5497.0 |
VPS33A | -5185.0 |
VPS11 | -5056.0 |
MAP1LC3B | -4785.0 |
TUFM | -3334.0 |
tRNA Aminoacylation
1165 | |
---|---|
set | tRNA Aminoacylation |
setSize | 22 |
pANOVA | 0.00321 |
s.dist | -0.363 |
p.adjustANOVA | 0.117 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NARS2 | -8388.0 |
DARS2 | -8101.5 |
HARS2 | -7957.5 |
MARS2 | -7890.0 |
FARSB | -7844.0 |
AIMP2 | -7587.5 |
EARS2 | -7568.5 |
CARS2 | -7259.0 |
RARS2 | -7219.5 |
IARS2 | -7183.0 |
AARS2 | -6759.0 |
FARS2 | -6024.5 |
PARS2 | -5702.0 |
SARS2 | -5543.5 |
EEF1E1 | -5514.0 |
YARS2 | -4648.0 |
FARSA | -4442.0 |
PPA1 | -3935.0 |
PPA2 | -3617.0 |
WARS2 | -1872.0 |
GeneID | Gene Rank |
---|---|
NARS2 | -8388.0 |
DARS2 | -8101.5 |
HARS2 | -7957.5 |
MARS2 | -7890.0 |
FARSB | -7844.0 |
AIMP2 | -7587.5 |
EARS2 | -7568.5 |
CARS2 | -7259.0 |
RARS2 | -7219.5 |
IARS2 | -7183.0 |
AARS2 | -6759.0 |
FARS2 | -6024.5 |
PARS2 | -5702.0 |
SARS2 | -5543.5 |
EEF1E1 | -5514.0 |
YARS2 | -4648.0 |
FARSA | -4442.0 |
PPA1 | -3935.0 |
PPA2 | -3617.0 |
WARS2 | -1872.0 |
VARS2 | -1656.0 |
TARS2 | -1190.0 |
Processing of Intronless Pre-mRNAs
712 | |
---|---|
set | Processing of Intronless Pre-mRNAs |
setSize | 15 |
pANOVA | 0.0153 |
s.dist | -0.362 |
p.adjustANOVA | 0.197 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CLP1 | -8773.0 |
NUDT21 | -8451.5 |
CSTF1 | -8202.5 |
CPSF2 | -7963.5 |
PAPOLA | -7720.0 |
CPSF1 | -7599.0 |
SYMPK | -7355.0 |
NCBP1 | -6163.5 |
CPSF3 | -5893.5 |
FIP1L1 | -5106.0 |
PABPN1 | -4971.0 |
CPSF4 | -4246.5 |
WDR33 | -3644.0 |
NCBP2 | -1030.5 |
CPSF6 | 0.5 |
GeneID | Gene Rank |
---|---|
CLP1 | -8773.0 |
NUDT21 | -8451.5 |
CSTF1 | -8202.5 |
CPSF2 | -7963.5 |
PAPOLA | -7720.0 |
CPSF1 | -7599.0 |
SYMPK | -7355.0 |
NCBP1 | -6163.5 |
CPSF3 | -5893.5 |
FIP1L1 | -5106.0 |
PABPN1 | -4971.0 |
CPSF4 | -4246.5 |
WDR33 | -3644.0 |
NCBP2 | -1030.5 |
CPSF6 | 0.5 |
Mitochondrial tRNA aminoacylation
555 | |
---|---|
set | Mitochondrial tRNA aminoacylation |
setSize | 17 |
pANOVA | 0.0102 |
s.dist | -0.36 |
p.adjustANOVA | 0.16 |
Top enriched genes
GeneID | Gene Rank |
---|---|
NARS2 | -8388.0 |
DARS2 | -8101.5 |
HARS2 | -7957.5 |
MARS2 | -7890.0 |
EARS2 | -7568.5 |
CARS2 | -7259.0 |
RARS2 | -7219.5 |
IARS2 | -7183.0 |
AARS2 | -6759.0 |
FARS2 | -6024.5 |
PARS2 | -5702.0 |
SARS2 | -5543.5 |
YARS2 | -4648.0 |
PPA2 | -3617.0 |
WARS2 | -1872.0 |
VARS2 | -1656.0 |
TARS2 | -1190.0 |
GeneID | Gene Rank |
---|---|
NARS2 | -8388.0 |
DARS2 | -8101.5 |
HARS2 | -7957.5 |
MARS2 | -7890.0 |
EARS2 | -7568.5 |
CARS2 | -7259.0 |
RARS2 | -7219.5 |
IARS2 | -7183.0 |
AARS2 | -6759.0 |
FARS2 | -6024.5 |
PARS2 | -5702.0 |
SARS2 | -5543.5 |
YARS2 | -4648.0 |
PPA2 | -3617.0 |
WARS2 | -1872.0 |
VARS2 | -1656.0 |
TARS2 | -1190.0 |
Mucopolysaccharidoses
569 | |
---|---|
set | Mucopolysaccharidoses |
setSize | 10 |
pANOVA | 0.0532 |
s.dist | 0.353 |
p.adjustANOVA | 0.331 |
Top enriched genes
GeneID | Gene Rank |
---|---|
HYAL1 | 0.5 |
GALNS | -739.5 |
SGSH | -971.5 |
IDUA | -1665.5 |
HGSNAT | -1808.0 |
GLB1 | -2090.5 |
ARSB | -2116.0 |
GUSB | -3581.0 |
GNS | -4037.0 |
NAGLU | -5949.0 |
GeneID | Gene Rank |
---|---|
HYAL1 | 0.5 |
GALNS | -739.5 |
SGSH | -971.5 |
IDUA | -1665.5 |
HGSNAT | -1808.0 |
GLB1 | -2090.5 |
ARSB | -2116.0 |
GUSB | -3581.0 |
GNS | -4037.0 |
NAGLU | -5949.0 |
HDMs demethylate histones
390 | |
---|---|
set | HDMs demethylate histones |
setSize | 15 |
pANOVA | 0.0199 |
s.dist | -0.347 |
p.adjustANOVA | 0.219 |
Top enriched genes
GeneID | Gene Rank |
---|---|
KDM4A | -8848.0 |
KDM6B | -8725.0 |
KDM2A | -8711.0 |
KDM1A | -7955.0 |
KDM3A | -7939.0 |
KDM5A | -7913.0 |
KDM2B | -7640.0 |
KDM4C | -7422.0 |
KDM1B | -7228.5 |
JMJD6 | -4024.5 |
ARID5B | -3611.0 |
MINA | -2120.0 |
KDM4D | -2052.5 |
KDM4B | -1273.0 |
KDM3B | -602.0 |
GeneID | Gene Rank |
---|---|
KDM4A | -8848.0 |
KDM6B | -8725.0 |
KDM2A | -8711.0 |
KDM1A | -7955.0 |
KDM3A | -7939.0 |
KDM5A | -7913.0 |
KDM2B | -7640.0 |
KDM4C | -7422.0 |
KDM1B | -7228.5 |
JMJD6 | -4024.5 |
ARID5B | -3611.0 |
MINA | -2120.0 |
KDM4D | -2052.5 |
KDM4B | -1273.0 |
KDM3B | -602.0 |
Collagen degradation
156 | |
---|---|
set | Collagen degradation |
setSize | 10 |
pANOVA | 0.0594 |
s.dist | 0.344 |
p.adjustANOVA | 0.342 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FURIN | 0.5 |
COL9A2 | -603.0 |
ADAM9 | -822.5 |
CTSD | -860.5 |
ADAM10 | -1021.0 |
CTSB | -2370.0 |
COL23A1 | -2745.0 |
COL19A1 | -3064.0 |
MMP15 | -4235.0 |
ADAM17 | -7668.0 |
GeneID | Gene Rank |
---|---|
FURIN | 0.5 |
COL9A2 | -603.0 |
ADAM9 | -822.5 |
CTSD | -860.5 |
ADAM10 | -1021.0 |
CTSB | -2370.0 |
COL23A1 | -2745.0 |
COL19A1 | -3064.0 |
MMP15 | -4235.0 |
ADAM17 | -7668.0 |
Erythropoietin activates RAS
282 | |
---|---|
set | Erythropoietin activates RAS |
setSize | 10 |
pANOVA | 0.0594 |
s.dist | 0.344 |
p.adjustANOVA | 0.342 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IRS2 | 875.0 |
EPOR | 757.0 |
JAK2 | 0.5 |
HRAS | -508.0 |
RAPGEF1 | -665.0 |
GRB2 | -2995.0 |
KRAS | -3095.0 |
CRKL | -4536.0 |
VAV1 | -5496.0 |
SHC1 | -7728.5 |
GeneID | Gene Rank |
---|---|
IRS2 | 875.0 |
EPOR | 757.0 |
JAK2 | 0.5 |
HRAS | -508.0 |
RAPGEF1 | -665.0 |
GRB2 | -2995.0 |
KRAS | -3095.0 |
CRKL | -4536.0 |
VAV1 | -5496.0 |
SHC1 | -7728.5 |
Interleukin-20 family signaling
463 | |
---|---|
set | Interleukin-20 family signaling |
setSize | 13 |
pANOVA | 0.0362 |
s.dist | 0.336 |
p.adjustANOVA | 0.272 |
Top enriched genes
GeneID | Gene Rank |
---|---|
SOCS3 | 652.0 |
IL19 | 0.5 |
JAK2 | 0.5 |
JAK1 | -838.0 |
STAT2 | -877.0 |
STAT5A | -929.0 |
STAT5B | -1073.0 |
STAT3 | -2825.0 |
IL10RB | -3086.0 |
STAT4 | -3326.0 |
TYK2 | -3971.0 |
PTPN11 | -6287.0 |
STAT1 | -8416.0 |
GeneID | Gene Rank |
---|---|
SOCS3 | 652.0 |
IL19 | 0.5 |
JAK2 | 0.5 |
JAK1 | -838.0 |
STAT2 | -877.0 |
STAT5A | -929.0 |
STAT5B | -1073.0 |
STAT3 | -2825.0 |
IL10RB | -3086.0 |
STAT4 | -3326.0 |
TYK2 | -3971.0 |
PTPN11 | -6287.0 |
STAT1 | -8416.0 |
RIPK1-mediated regulated necrosis
764 | |
---|---|
set | RIPK1-mediated regulated necrosis |
setSize | 24 |
pANOVA | 0.00458 |
s.dist | -0.334 |
p.adjustANOVA | 0.117 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
FAS | -8683.5 |
UBC | -8547.0 |
FLOT1 | -7796.0 |
CFLAR | -7775.0 |
RIPK3 | -7627.0 |
UBB | -7240.0 |
FLOT2 | -7092.0 |
HSP90AA1 | -6691.0 |
TRADD | -6427.5 |
PELI1 | -6415.0 |
CASP8 | -6169.0 |
TNFRSF10A | -6070.0 |
BIRC2 | -5780.0 |
CDC37 | -5647.5 |
TNFRSF10B | -5205.0 |
TRAF2 | -4778.0 |
PDCD6IP | -4136.0 |
STUB1 | -3895.0 |
BIRC3 | -3734.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
FAS | -8683.5 |
UBC | -8547.0 |
FLOT1 | -7796.0 |
CFLAR | -7775.0 |
RIPK3 | -7627.0 |
UBB | -7240.0 |
FLOT2 | -7092.0 |
HSP90AA1 | -6691.0 |
TRADD | -6427.5 |
PELI1 | -6415.0 |
CASP8 | -6169.0 |
TNFRSF10A | -6070.0 |
BIRC2 | -5780.0 |
CDC37 | -5647.5 |
TNFRSF10B | -5205.0 |
TRAF2 | -4778.0 |
PDCD6IP | -4136.0 |
STUB1 | -3895.0 |
BIRC3 | -3734.0 |
TNFSF10 | -2568.0 |
MLKL | -2389.0 |
FADD | -2144.0 |
UBA52 | -634.0 |
Regulation of necroptotic cell death
850 | |
---|---|
set | Regulation of necroptotic cell death |
setSize | 24 |
pANOVA | 0.00458 |
s.dist | -0.334 |
p.adjustANOVA | 0.117 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
FAS | -8683.5 |
UBC | -8547.0 |
FLOT1 | -7796.0 |
CFLAR | -7775.0 |
RIPK3 | -7627.0 |
UBB | -7240.0 |
FLOT2 | -7092.0 |
HSP90AA1 | -6691.0 |
TRADD | -6427.5 |
PELI1 | -6415.0 |
CASP8 | -6169.0 |
TNFRSF10A | -6070.0 |
BIRC2 | -5780.0 |
CDC37 | -5647.5 |
TNFRSF10B | -5205.0 |
TRAF2 | -4778.0 |
PDCD6IP | -4136.0 |
STUB1 | -3895.0 |
BIRC3 | -3734.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
FAS | -8683.5 |
UBC | -8547.0 |
FLOT1 | -7796.0 |
CFLAR | -7775.0 |
RIPK3 | -7627.0 |
UBB | -7240.0 |
FLOT2 | -7092.0 |
HSP90AA1 | -6691.0 |
TRADD | -6427.5 |
PELI1 | -6415.0 |
CASP8 | -6169.0 |
TNFRSF10A | -6070.0 |
BIRC2 | -5780.0 |
CDC37 | -5647.5 |
TNFRSF10B | -5205.0 |
TRAF2 | -4778.0 |
PDCD6IP | -4136.0 |
STUB1 | -3895.0 |
BIRC3 | -3734.0 |
TNFSF10 | -2568.0 |
MLKL | -2389.0 |
FADD | -2144.0 |
UBA52 | -634.0 |
Activation of G protein gated Potassium channels
29 | |
---|---|
set | Activation of G protein gated Potassium channels |
setSize | 10 |
pANOVA | 0.0709 |
s.dist | 0.33 |
p.adjustANOVA | 0.361 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
GNGT2 | 0.5 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
GNGT2 | 0.5 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
G protein gated Potassium channels
333 | |
---|---|
set | G protein gated Potassium channels |
setSize | 10 |
pANOVA | 0.0709 |
s.dist | 0.33 |
p.adjustANOVA | 0.361 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
GNGT2 | 0.5 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
GNGT2 | 0.5 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits
434 | |
---|---|
set | Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits |
setSize | 10 |
pANOVA | 0.0709 |
s.dist | 0.33 |
p.adjustANOVA | 0.361 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
GNGT2 | 0.5 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GABBR1 | 0.5 |
GNGT2 | 0.5 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
Caspase activation via Death Receptors in the presence of ligand
116 | |
---|---|
set | Caspase activation via Death Receptors in the presence of ligand |
setSize | 10 |
pANOVA | 0.0711 |
s.dist | -0.33 |
p.adjustANOVA | 0.361 |
Top enriched genes
GeneID | Gene Rank |
---|---|
FAS | -8683.5 |
CFLAR | -7775.0 |
TICAM1 | -6700.0 |
TRADD | -6427.5 |
CASP8 | -6169.0 |
TNFRSF10A | -6070.0 |
TNFRSF10B | -5205.0 |
TRAF2 | -4778.0 |
TNFSF10 | -2568.0 |
FADD | -2144.0 |
GeneID | Gene Rank |
---|---|
FAS | -8683.5 |
CFLAR | -7775.0 |
TICAM1 | -6700.0 |
TRADD | -6427.5 |
CASP8 | -6169.0 |
TNFRSF10A | -6070.0 |
TNFRSF10B | -5205.0 |
TRAF2 | -4778.0 |
TNFSF10 | -2568.0 |
FADD | -2144.0 |
Activation of kainate receptors upon glutamate binding
37 | |
---|---|
set | Activation of kainate receptors upon glutamate binding |
setSize | 15 |
pANOVA | 0.0272 |
s.dist | 0.329 |
p.adjustANOVA | 0.248 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
DLG1 | 633.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
NCALD | 0.5 |
GNGT2 | 0.5 |
CALM1 | -817.0 |
PLCB3 | -933.0 |
GNG5 | -3127.5 |
DLG4 | -3314.0 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
PLCB2 | -7661.0 |
GNB2 | -8449.0 |
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
DLG1 | 633.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
NCALD | 0.5 |
GNGT2 | 0.5 |
CALM1 | -817.0 |
PLCB3 | -933.0 |
GNG5 | -3127.5 |
DLG4 | -3314.0 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
PLCB2 | -7661.0 |
GNB2 | -8449.0 |
Signaling by Erythropoietin
942 | |
---|---|
set | Signaling by Erythropoietin |
setSize | 18 |
pANOVA | 0.0158 |
s.dist | 0.329 |
p.adjustANOVA | 0.197 |
Top enriched genes
GeneID | Gene Rank |
---|---|
IRS2 | 875.0 |
EPOR | 757.0 |
JAK2 | 0.5 |
HRAS | -508.0 |
RAPGEF1 | -665.0 |
STAT5A | -929.0 |
STAT5B | -1073.0 |
PLCG1 | -1151.0 |
PIK3CA | -1214.0 |
PIK3CD | -2551.0 |
PIK3R5 | -2838.0 |
GRB2 | -2995.0 |
KRAS | -3095.0 |
CRKL | -4536.0 |
PIK3R1 | -4577.0 |
VAV1 | -5496.0 |
PLCG2 | -5781.0 |
SHC1 | -7728.5 |
GeneID | Gene Rank |
---|---|
IRS2 | 875.0 |
EPOR | 757.0 |
JAK2 | 0.5 |
HRAS | -508.0 |
RAPGEF1 | -665.0 |
STAT5A | -929.0 |
STAT5B | -1073.0 |
PLCG1 | -1151.0 |
PIK3CA | -1214.0 |
PIK3CD | -2551.0 |
PIK3R5 | -2838.0 |
GRB2 | -2995.0 |
KRAS | -3095.0 |
CRKL | -4536.0 |
PIK3R1 | -4577.0 |
VAV1 | -5496.0 |
PLCG2 | -5781.0 |
SHC1 | -7728.5 |
Translesion Synthesis by POLH
1097 | |
---|---|
set | Translesion Synthesis by POLH |
setSize | 16 |
pANOVA | 0.0235 |
s.dist | -0.327 |
p.adjustANOVA | 0.229 |
Top enriched genes
GeneID | Gene Rank |
---|---|
UFD1L | -8911.5 |
RPS27A | -8712.5 |
RFC5 | -8619.0 |
UBC | -8547.0 |
RFC3 | -8030.0 |
UBB | -7240.0 |
RPA3 | -6328.0 |
RFC2 | -5672.0 |
NPLOC4 | -5447.0 |
PCNA | -5027.0 |
VCP | -4870.0 |
RCHY1 | -4515.5 |
POLH | -3833.5 |
RPA1 | -3377.5 |
UBA52 | -634.0 |
RFC4 | -456.0 |
GeneID | Gene Rank |
---|---|
UFD1L | -8911.5 |
RPS27A | -8712.5 |
RFC5 | -8619.0 |
UBC | -8547.0 |
RFC3 | -8030.0 |
UBB | -7240.0 |
RPA3 | -6328.0 |
RFC2 | -5672.0 |
NPLOC4 | -5447.0 |
PCNA | -5027.0 |
VCP | -4870.0 |
RCHY1 | -4515.5 |
POLH | -3833.5 |
RPA1 | -3377.5 |
UBA52 | -634.0 |
RFC4 | -456.0 |
Impaired BRCA2 binding to RAD51
425 | |
---|---|
set | Impaired BRCA2 binding to RAD51 |
setSize | 30 |
pANOVA | 0.00196 |
s.dist | -0.327 |
p.adjustANOVA | 0.0919 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
ATR | -8697.0 |
RFC5 | -8619.0 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
KAT5 | -8198.0 |
RFC3 | -8030.0 |
RAD9B | -7770.5 |
BLM | -7501.0 |
RMI1 | -7389.5 |
DNA2 | -7266.0 |
TOP3A | -7020.5 |
RAD1 | -6683.5 |
RPA3 | -6328.0 |
EXO1 | -6078.0 |
RFC2 | -5672.0 |
HUS1 | -5490.0 |
RAD17 | -5393.5 |
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
ATR | -8697.0 |
RFC5 | -8619.0 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
KAT5 | -8198.0 |
RFC3 | -8030.0 |
RAD9B | -7770.5 |
BLM | -7501.0 |
RMI1 | -7389.5 |
DNA2 | -7266.0 |
TOP3A | -7020.5 |
RAD1 | -6683.5 |
RPA3 | -6328.0 |
EXO1 | -6078.0 |
RFC2 | -5672.0 |
HUS1 | -5490.0 |
RAD17 | -5393.5 |
WRN | -4029.5 |
RPA1 | -3377.5 |
RAD9A | -3132.0 |
TOPBP1 | -3108.0 |
ATRIP | -2471.0 |
RAD50 | -1967.0 |
NBN | -1658.0 |
RFC4 | -456.0 |
BARD1 | -363.0 |
BRIP1 | 349.0 |
Mitochondrial calcium ion transport
552 | |
---|---|
set | Mitochondrial calcium ion transport |
setSize | 14 |
pANOVA | 0.0347 |
s.dist | 0.326 |
p.adjustANOVA | 0.268 |
Top enriched genes
GeneID | Gene Rank |
---|---|
VDAC1 | 369.0 |
PHB | 0.5 |
SLC8A3 | -327.0 |
PMPCB | -418.0 |
PARL | -539.0 |
LETM1 | -558.0 |
AFG3L2 | -965.0 |
STOML2 | -1249.0 |
AKAP1 | -2965.0 |
C2orf47 | -3718.5 |
YME1L1 | -3986.5 |
SPG7 | -5019.0 |
VDAC3 | -6667.0 |
PHB2 | -7976.5 |
GeneID | Gene Rank |
---|---|
VDAC1 | 369.0 |
PHB | 0.5 |
SLC8A3 | -327.0 |
PMPCB | -418.0 |
PARL | -539.0 |
LETM1 | -558.0 |
AFG3L2 | -965.0 |
STOML2 | -1249.0 |
AKAP1 | -2965.0 |
C2orf47 | -3718.5 |
YME1L1 | -3986.5 |
SPG7 | -5019.0 |
VDAC3 | -6667.0 |
PHB2 | -7976.5 |
Golgi Cisternae Pericentriolar Stack Reorganization
382 | |
---|---|
set | Golgi Cisternae Pericentriolar Stack Reorganization |
setSize | 14 |
pANOVA | 0.0358 |
s.dist | -0.324 |
p.adjustANOVA | 0.272 |
Top enriched genes
GeneID | Gene Rank |
---|---|
BLZF1 | -8775.5 |
RAB1B | -8437.0 |
USO1 | -8317.0 |
CCNB1 | -7466.0 |
RAB2A | -7141.0 |
RAB1A | -5713.0 |
MAPK3 | -5593.0 |
CCNB2 | -5187.0 |
GOLGA2 | -4449.5 |
PLK1 | -4291.0 |
CDK1 | -4141.5 |
GORASP1 | -3687.5 |
MAPK1 | -3485.0 |
GORASP2 | -2051.0 |
GeneID | Gene Rank |
---|---|
BLZF1 | -8775.5 |
RAB1B | -8437.0 |
USO1 | -8317.0 |
CCNB1 | -7466.0 |
RAB2A | -7141.0 |
RAB1A | -5713.0 |
MAPK3 | -5593.0 |
CCNB2 | -5187.0 |
GOLGA2 | -4449.5 |
PLK1 | -4291.0 |
CDK1 | -4141.5 |
GORASP1 | -3687.5 |
MAPK1 | -3485.0 |
GORASP2 | -2051.0 |
Interleukin-10 signaling
457 | |
---|---|
set | Interleukin-10 signaling |
setSize | 12 |
pANOVA | 0.0521 |
s.dist | 0.324 |
p.adjustANOVA | 0.327 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CCR1 | 768.0 |
TNFRSF1A | 0.5 |
IL10RA | -775.0 |
JAK1 | -838.0 |
TNF | -1324.0 |
STAT3 | -2825.0 |
IL10RB | -3086.0 |
CSF1 | -3126.0 |
IL12A | -3564.0 |
TNFRSF1B | -3794.0 |
TYK2 | -3971.0 |
ICAM1 | -6745.0 |
GeneID | Gene Rank |
---|---|
CCR1 | 768.0 |
TNFRSF1A | 0.5 |
IL10RA | -775.0 |
JAK1 | -838.0 |
TNF | -1324.0 |
STAT3 | -2825.0 |
IL10RB | -3086.0 |
CSF1 | -3126.0 |
IL12A | -3564.0 |
TNFRSF1B | -3794.0 |
TYK2 | -3971.0 |
ICAM1 | -6745.0 |
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
1118 | |
---|---|
set | Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA |
setSize | 15 |
pANOVA | 0.0308 |
s.dist | -0.322 |
p.adjustANOVA | 0.261 |
Top enriched genes
GeneID | Gene Rank |
---|---|
YWHAB | -8384.0 |
EXOSC8 | -7726.0 |
DCP2 | -7526.0 |
EXOSC7 | -7156.5 |
DIS3 | -7121.5 |
EXOSC2 | -7070.0 |
ZFP36 | -7042.0 |
DCP1A | -6234.0 |
EXOSC4 | -5984.0 |
EXOSC5 | -5558.5 |
EXOSC1 | -5102.5 |
MAPKAPK2 | -4780.0 |
TNPO1 | -2833.0 |
EXOSC6 | -1100.0 |
EXOSC3 | -598.0 |
GeneID | Gene Rank |
---|---|
YWHAB | -8384.0 |
EXOSC8 | -7726.0 |
DCP2 | -7526.0 |
EXOSC7 | -7156.5 |
DIS3 | -7121.5 |
EXOSC2 | -7070.0 |
ZFP36 | -7042.0 |
DCP1A | -6234.0 |
EXOSC4 | -5984.0 |
EXOSC5 | -5558.5 |
EXOSC1 | -5102.5 |
MAPKAPK2 | -4780.0 |
TNPO1 | -2833.0 |
EXOSC6 | -1100.0 |
EXOSC3 | -598.0 |
Chaperone Mediated Autophagy
136 | |
---|---|
set | Chaperone Mediated Autophagy |
setSize | 12 |
pANOVA | 0.0544 |
s.dist | -0.321 |
p.adjustANOVA | 0.336 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
ARL13B | -7442.0 |
PARK7 | -7246.0 |
UBB | -7240.0 |
HSP90AA1 | -6691.0 |
EEF1A1 | -6367.0 |
HSP90AB1 | -6165.0 |
PLIN3 | -4399.0 |
PCNT | -2266.0 |
PLIN2 | -1586.0 |
UBA52 | -634.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
ARL13B | -7442.0 |
PARK7 | -7246.0 |
UBB | -7240.0 |
HSP90AA1 | -6691.0 |
EEF1A1 | -6367.0 |
HSP90AB1 | -6165.0 |
PLIN3 | -4399.0 |
PCNT | -2266.0 |
PLIN2 | -1586.0 |
UBA52 | -634.0 |
Downregulation of ERBB2 signaling
245 | |
---|---|
set | Downregulation of ERBB2 signaling |
setSize | 17 |
pANOVA | 0.0222 |
s.dist | -0.32 |
p.adjustANOVA | 0.223 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
RNF41 | -8704.0 |
PTPN12 | -8616.0 |
UBC | -8547.0 |
PTPN18 | -7656.0 |
UBB | -7240.0 |
CUL5 | -6794.0 |
HSP90AA1 | -6691.0 |
USP8 | -6334.0 |
HBEGF | -5667.0 |
CDC37 | -5647.5 |
ERBB2 | -4746.5 |
STUB1 | -3895.0 |
AKT2 | -3115.0 |
AKT1 | -2293.0 |
UBA52 | -634.0 |
ERBB3 | 0.5 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
RNF41 | -8704.0 |
PTPN12 | -8616.0 |
UBC | -8547.0 |
PTPN18 | -7656.0 |
UBB | -7240.0 |
CUL5 | -6794.0 |
HSP90AA1 | -6691.0 |
USP8 | -6334.0 |
HBEGF | -5667.0 |
CDC37 | -5647.5 |
ERBB2 | -4746.5 |
STUB1 | -3895.0 |
AKT2 | -3115.0 |
AKT1 | -2293.0 |
UBA52 | -634.0 |
ERBB3 | 0.5 |
TICAM1, RIP1-mediated IKK complex recruitment
1032 | |
---|---|
set | TICAM1, RIP1-mediated IKK complex recruitment |
setSize | 17 |
pANOVA | 0.0225 |
s.dist | -0.32 |
p.adjustANOVA | 0.223 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
CHUK | -8055.0 |
RIPK3 | -7627.0 |
IKBKB | -7351.0 |
TRAF6 | -7283.0 |
UBB | -7240.0 |
UBE2D2 | -6859.0 |
TICAM1 | -6700.0 |
BIRC2 | -5780.0 |
UBE2V1 | -5429.0 |
UBE2D1 | -4090.0 |
UBE2N | -4053.0 |
BIRC3 | -3734.0 |
TLR3 | -1577.0 |
UBE2D3 | -1554.5 |
UBA52 | -634.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
CHUK | -8055.0 |
RIPK3 | -7627.0 |
IKBKB | -7351.0 |
TRAF6 | -7283.0 |
UBB | -7240.0 |
UBE2D2 | -6859.0 |
TICAM1 | -6700.0 |
BIRC2 | -5780.0 |
UBE2V1 | -5429.0 |
UBE2D1 | -4090.0 |
UBE2N | -4053.0 |
BIRC3 | -3734.0 |
TLR3 | -1577.0 |
UBE2D3 | -1554.5 |
UBA52 | -634.0 |
RHO GTPases activate CIT
746 | |
---|---|
set | RHO GTPases activate CIT |
setSize | 14 |
pANOVA | 0.0387 |
s.dist | -0.319 |
p.adjustANOVA | 0.276 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RHOA | -8845.5 |
PPP1R12A | -8747.0 |
KIF14 | -8455.0 |
PPP1R12B | -8133.0 |
CIT | -7187.0 |
MYL6 | -7079.0 |
CDKN1B | -6833.0 |
MYH10 | -5399.0 |
RHOB | -4872.0 |
MYH9 | -3866.0 |
DLG4 | -3314.0 |
RAC1 | -2453.0 |
PPP1CB | -1680.0 |
PRC1 | -1532.0 |
GeneID | Gene Rank |
---|---|
RHOA | -8845.5 |
PPP1R12A | -8747.0 |
KIF14 | -8455.0 |
PPP1R12B | -8133.0 |
CIT | -7187.0 |
MYL6 | -7079.0 |
CDKN1B | -6833.0 |
MYH10 | -5399.0 |
RHOB | -4872.0 |
MYH9 | -3866.0 |
DLG4 | -3314.0 |
RAC1 | -2453.0 |
PPP1CB | -1680.0 |
PRC1 | -1532.0 |
Glycogen synthesis
376 | |
---|---|
set | Glycogen synthesis |
setSize | 11 |
pANOVA | 0.0669 |
s.dist | -0.319 |
p.adjustANOVA | 0.36 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UGP2 | -8608.0 |
UBC | -8547.0 |
PGM2 | -8095.0 |
PGM1 | -7755.0 |
UBB | -7240.0 |
GYS1 | -5628.5 |
PGM2L1 | -4508.0 |
GYG1 | -2723.0 |
UBA52 | -634.0 |
NHLRC1 | 856.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UGP2 | -8608.0 |
UBC | -8547.0 |
PGM2 | -8095.0 |
PGM1 | -7755.0 |
UBB | -7240.0 |
GYS1 | -5628.5 |
PGM2L1 | -4508.0 |
GYG1 | -2723.0 |
UBA52 | -634.0 |
NHLRC1 | 856.0 |
Signaling by WNT in cancer
995 | |
---|---|
set | Signaling by WNT in cancer |
setSize | 22 |
pANOVA | 0.0104 |
s.dist | 0.316 |
p.adjustANOVA | 0.16 |
Top enriched genes
GeneID | Gene Rank |
---|---|
WNT3A | 823.0 |
FZD8 | 717.0 |
CTBP1 | 0.5 |
LRP5 | 0.5 |
FZD5 | -735.0 |
LRP6 | -954.0 |
PPP2R5E | -1172.0 |
PPP2R1B | -1211.0 |
GSK3B | -1568.0 |
PPP2CB | -1685.0 |
AXIN1 | -2143.0 |
CSNK1A1 | -2210.0 |
TNKS2 | -2298.0 |
TNKS | -2848.0 |
PPP2R5D | -3194.0 |
FZD6 | -3925.0 |
PPP2R5C | -3931.0 |
APC | -4548.0 |
PPP2R5A | -5091.0 |
PPP2R5B | -6090.0 |
GeneID | Gene Rank |
---|---|
WNT3A | 823.0 |
FZD8 | 717.0 |
CTBP1 | 0.5 |
LRP5 | 0.5 |
FZD5 | -735.0 |
LRP6 | -954.0 |
PPP2R5E | -1172.0 |
PPP2R1B | -1211.0 |
GSK3B | -1568.0 |
PPP2CB | -1685.0 |
AXIN1 | -2143.0 |
CSNK1A1 | -2210.0 |
TNKS2 | -2298.0 |
TNKS | -2848.0 |
PPP2R5D | -3194.0 |
FZD6 | -3925.0 |
PPP2R5C | -3931.0 |
APC | -4548.0 |
PPP2R5A | -5091.0 |
PPP2R5B | -6090.0 |
CTNNB1 | -6204.0 |
PPP2CA | -6314.0 |
Cytosolic sulfonation of small molecules
179 | |
---|---|
set | Cytosolic sulfonation of small molecules |
setSize | 10 |
pANOVA | 0.0847 |
s.dist | 0.315 |
p.adjustANOVA | 0.39 |
Top enriched genes
GeneID | Gene Rank |
---|---|
TPST1 | 405.0 |
PODXL2 | 0.5 |
SLC35B2 | -1288.0 |
TPST2 | -1422.0 |
SLC26A1 | -1665.5 |
BPNT1 | -3219.0 |
SLC35B3 | -3318.0 |
ABHD14B | -4039.5 |
PAPSS1 | -4204.0 |
SLC26A2 | -6087.0 |
GeneID | Gene Rank |
---|---|
TPST1 | 405.0 |
PODXL2 | 0.5 |
SLC35B2 | -1288.0 |
TPST2 | -1422.0 |
SLC26A1 | -1665.5 |
BPNT1 | -3219.0 |
SLC35B3 | -3318.0 |
ABHD14B | -4039.5 |
PAPSS1 | -4204.0 |
SLC26A2 | -6087.0 |
Negative regulation of FLT3
602 | |
---|---|
set | Negative regulation of FLT3 |
setSize | 10 |
pANOVA | 0.0848 |
s.dist | -0.315 |
p.adjustANOVA | 0.39 |
Top enriched genes
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
FLT3LG | -8264.0 |
UBB | -7240.0 |
CSK | -6881.0 |
CBL | -5176.0 |
SOCS2 | -4505.0 |
ABL2 | -3394.0 |
SH2B3 | -2434.0 |
UBA52 | -634.0 |
GeneID | Gene Rank |
---|---|
RPS27A | -8712.5 |
UBC | -8547.0 |
FLT3LG | -8264.0 |
UBB | -7240.0 |
CSK | -6881.0 |
CBL | -5176.0 |
SOCS2 | -4505.0 |
ABL2 | -3394.0 |
SH2B3 | -2434.0 |
UBA52 | -634.0 |
Cell-cell junction organization
127 | |
---|---|
set | Cell-cell junction organization |
setSize | 12 |
pANOVA | 0.0593 |
s.dist | 0.315 |
p.adjustANOVA | 0.342 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CTNND1 | 797.0 |
PARD6A | 556.5 |
SDK2 | 0.5 |
PARD6B | -546.0 |
CDH24 | -613.0 |
CLDN1 | -1469.0 |
CLDN12 | -1949.0 |
ANG | -3052.5 |
F11R | -4158.0 |
PRKCI | -5240.0 |
CTNNB1 | -6204.0 |
MPP5 | -7953.0 |
GeneID | Gene Rank |
---|---|
CTNND1 | 797.0 |
PARD6A | 556.5 |
SDK2 | 0.5 |
PARD6B | -546.0 |
CDH24 | -613.0 |
CLDN1 | -1469.0 |
CLDN12 | -1949.0 |
ANG | -3052.5 |
F11R | -4158.0 |
PRKCI | -5240.0 |
CTNNB1 | -6204.0 |
MPP5 | -7953.0 |
Generation of second messenger molecules
362 | |
---|---|
set | Generation of second messenger molecules |
setSize | 12 |
pANOVA | 0.0606 |
s.dist | 0.313 |
p.adjustANOVA | 0.343 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CD247 | 729.0 |
GRAP2 | 0.5 |
ITK | 0.5 |
PAK1 | -1126.0 |
PLCG1 | -1151.0 |
LCK | -1992.0 |
EVL | -2347.0 |
VASP | -3111.0 |
NCK1 | -3899.0 |
PAK2 | -5011.0 |
PLCG2 | -5781.0 |
LCP2 | -6236.0 |
GeneID | Gene Rank |
---|---|
CD247 | 729.0 |
GRAP2 | 0.5 |
ITK | 0.5 |
PAK1 | -1126.0 |
PLCG1 | -1151.0 |
LCK | -1992.0 |
EVL | -2347.0 |
VASP | -3111.0 |
NCK1 | -3899.0 |
PAK2 | -5011.0 |
PLCG2 | -5781.0 |
LCP2 | -6236.0 |
Meiosis
518 | |
---|---|
set | Meiosis |
setSize | 39 |
pANOVA | 0.000785 |
s.dist | -0.311 |
p.adjustANOVA | 0.051 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
TINF2 | -8852.0 |
BRCA1 | -8797.5 |
MSH5 | -8789.0 |
ATR | -8697.0 |
TERF2 | -8593.0 |
DIDO1 | -8591.0 |
BRCA2 | -8433.0 |
HSPA2 | -8393.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
RAD21 | -8077.0 |
PSMC3IP | -8067.0 |
SMC3 | -8017.0 |
MND1 | -7741.0 |
BLM | -7501.0 |
REC8 | -7385.0 |
TOP3A | -7020.5 |
LMNB1 | -6686.0 |
RPA3 | -6328.0 |
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
TINF2 | -8852.0 |
BRCA1 | -8797.5 |
MSH5 | -8789.0 |
ATR | -8697.0 |
TERF2 | -8593.0 |
DIDO1 | -8591.0 |
BRCA2 | -8433.0 |
HSPA2 | -8393.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
RAD21 | -8077.0 |
PSMC3IP | -8067.0 |
SMC3 | -8017.0 |
MND1 | -7741.0 |
BLM | -7501.0 |
REC8 | -7385.0 |
TOP3A | -7020.5 |
LMNB1 | -6686.0 |
RPA3 | -6328.0 |
CDK4 | -6073.0 |
UBE2I | -5674.0 |
MLH3 | -5573.0 |
TERF2IP | -5172.5 |
DMC1 | -4318.0 |
STAG1 | -4295.0 |
TERF1 | -3820.0 |
H2AFX | -3494.0 |
RPA1 | -3377.5 |
CDK2 | -3323.5 |
SYCE2 | -2919.0 |
SYNE1 | -2672.0 |
RAD50 | -1967.0 |
NBN | -1658.0 |
SYNE2 | -1193.0 |
STAG3 | -675.5 |
LMNA | 0.5 |
SMC1B | 396.5 |
ACD | 556.5 |
Prostacyclin signalling through prostacyclin receptor
717 | |
---|---|
set | Prostacyclin signalling through prostacyclin receptor |
setSize | 10 |
pANOVA | 0.0892 |
s.dist | 0.31 |
p.adjustANOVA | 0.394 |
Top enriched genes
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GNGT2 | 0.5 |
GNAS | -956.0 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
GeneID | Gene Rank |
---|---|
GNG4 | 869.0 |
GNG2 | 620.0 |
GNG12 | 0.5 |
GNGT2 | 0.5 |
GNAS | -956.0 |
GNG5 | -3127.5 |
GNB1 | -4107.0 |
GNB5 | -4674.0 |
GNG3 | -5234.0 |
GNB2 | -8449.0 |
Assembly and cell surface presentation of NMDA receptors
63 | |
---|---|
set | Assembly and cell surface presentation of NMDA receptors |
setSize | 12 |
pANOVA | 0.0637 |
s.dist | 0.309 |
p.adjustANOVA | 0.35 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DLG1 | 633.0 |
NBEA | 346.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
APBA1 | -992.0 |
KIF17 | -1599.0 |
DLG4 | -3314.0 |
LIN7B | -4774.0 |
LIN7C | -5707.5 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
GeneID | Gene Rank |
---|---|
DLG1 | 633.0 |
NBEA | 346.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
APBA1 | -992.0 |
KIF17 | -1599.0 |
DLG4 | -3314.0 |
LIN7B | -4774.0 |
LIN7C | -5707.5 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
Resolution of D-loop Structures through Holliday Junction Intermediates
860 | |
---|---|
set | Resolution of D-loop Structures through Holliday Junction Intermediates |
setSize | 24 |
pANOVA | 0.00901 |
s.dist | -0.308 |
p.adjustANOVA | 0.158 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
MUS81 | -8759.0 |
GEN1 | -8523.5 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
KAT5 | -8198.0 |
XRCC3 | -7805.5 |
BLM | -7501.0 |
RMI1 | -7389.5 |
DNA2 | -7266.0 |
TOP3A | -7020.5 |
EXO1 | -6078.0 |
XRCC2 | -4285.0 |
WRN | -4029.5 |
RAD51AP1 | -3956.5 |
EME2 | -2554.5 |
EME1 | -2531.5 |
RAD50 | -1967.0 |
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
MUS81 | -8759.0 |
GEN1 | -8523.5 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
KAT5 | -8198.0 |
XRCC3 | -7805.5 |
BLM | -7501.0 |
RMI1 | -7389.5 |
DNA2 | -7266.0 |
TOP3A | -7020.5 |
EXO1 | -6078.0 |
XRCC2 | -4285.0 |
WRN | -4029.5 |
RAD51AP1 | -3956.5 |
EME2 | -2554.5 |
EME1 | -2531.5 |
RAD50 | -1967.0 |
NBN | -1658.0 |
PALB2 | -839.5 |
BARD1 | -363.0 |
BRIP1 | 349.0 |
mRNA 3’-end processing
1147 | |
---|---|
set | mRNA 3’-end processing |
setSize | 30 |
pANOVA | 0.00418 |
s.dist | -0.302 |
p.adjustANOVA | 0.117 |
Top enriched genes
GeneID | Gene Rank |
---|---|
CLP1 | -8773.0 |
NUDT21 | -8451.5 |
CSTF1 | -8202.5 |
RNPS1 | -8181.0 |
CPSF2 | -7963.5 |
PAPOLA | -7720.0 |
CPSF1 | -7599.0 |
SYMPK | -7355.0 |
CASC3 | -7256.0 |
U2AF1 | -7242.0 |
SLU7 | -6879.0 |
THOC1 | -6676.0 |
THOC7 | -6528.0 |
U2AF1L4 | -6394.5 |
NCBP1 | -6163.5 |
FYTTD1 | -5944.0 |
CPSF3 | -5893.5 |
THOC6 | -5502.5 |
FIP1L1 | -5106.0 |
PABPN1 | -4971.0 |
GeneID | Gene Rank |
---|---|
CLP1 | -8773.0 |
NUDT21 | -8451.5 |
CSTF1 | -8202.5 |
RNPS1 | -8181.0 |
CPSF2 | -7963.5 |
PAPOLA | -7720.0 |
CPSF1 | -7599.0 |
SYMPK | -7355.0 |
CASC3 | -7256.0 |
U2AF1 | -7242.0 |
SLU7 | -6879.0 |
THOC1 | -6676.0 |
THOC7 | -6528.0 |
U2AF1L4 | -6394.5 |
NCBP1 | -6163.5 |
FYTTD1 | -5944.0 |
CPSF3 | -5893.5 |
THOC6 | -5502.5 |
FIP1L1 | -5106.0 |
PABPN1 | -4971.0 |
THOC5 | -4789.0 |
POLDIP3 | -4636.0 |
CPSF4 | -4246.5 |
SRRM1 | -3818.0 |
WDR33 | -3644.0 |
EIF4A3 | -2552.0 |
CDC40 | -1427.5 |
NCBP2 | -1030.5 |
U2AF2 | -492.0 |
CPSF6 | 0.5 |
Long-term potentiation
499 | |
---|---|
set | Long-term potentiation |
setSize | 10 |
pANOVA | 0.0989 |
s.dist | 0.301 |
p.adjustANOVA | 0.41 |
Top enriched genes
GeneID | Gene Rank |
---|---|
DLG1 | 633.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
CALM1 | -817.0 |
DLG4 | -3314.0 |
NRGN | -3353.0 |
SRC | -3915.0 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
GeneID | Gene Rank |
---|---|
DLG1 | 633.0 |
CAMK2G | 0.5 |
GRIN1 | 0.5 |
GRIN2D | 0.5 |
CALM1 | -817.0 |
DLG4 | -3314.0 |
NRGN | -3353.0 |
SRC | -3915.0 |
CAMK2D | -6176.0 |
DLG2 | -8562.0 |
Myogenesis
575 | |
---|---|
set | Myogenesis |
setSize | 13 |
pANOVA | 0.061 |
s.dist | -0.3 |
p.adjustANOVA | 0.343 |
Top enriched genes
GeneID | Gene Rank |
---|---|
MAPK14 | -8225.0 |
CDC42 | -8026.0 |
MEF2D | -7214.0 |
ABL1 | -6532.0 |
CTNNB1 | -6204.0 |
BNIP2 | -6168.0 |
MAP2K6 | -5905.0 |
MEF2A | -5468.0 |
TCF12 | -5416.0 |
NEO1 | -4706.0 |
SPAG9 | -4461.0 |
CDON | -3260.0 |
TCF3 | 0.5 |
GeneID | Gene Rank |
---|---|
MAPK14 | -8225.0 |
CDC42 | -8026.0 |
MEF2D | -7214.0 |
ABL1 | -6532.0 |
CTNNB1 | -6204.0 |
BNIP2 | -6168.0 |
MAP2K6 | -5905.0 |
MEF2A | -5468.0 |
TCF12 | -5416.0 |
NEO1 | -4706.0 |
SPAG9 | -4461.0 |
CDON | -3260.0 |
TCF3 | 0.5 |
Presynaptic phase of homologous DNA pairing and strand exchange
708 | |
---|---|
set | Presynaptic phase of homologous DNA pairing and strand exchange |
setSize | 32 |
pANOVA | 0.00367 |
s.dist | -0.297 |
p.adjustANOVA | 0.117 |
Top enriched genes
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
ATR | -8697.0 |
RFC5 | -8619.0 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
KAT5 | -8198.0 |
RFC3 | -8030.0 |
RAD9B | -7770.5 |
BLM | -7501.0 |
RMI1 | -7389.5 |
DNA2 | -7266.0 |
TOP3A | -7020.5 |
RAD1 | -6683.5 |
RPA3 | -6328.0 |
EXO1 | -6078.0 |
RFC2 | -5672.0 |
HUS1 | -5490.0 |
RAD17 | -5393.5 |
GeneID | Gene Rank |
---|---|
ATM | -8945.5 |
BRCA1 | -8797.5 |
ATR | -8697.0 |
RFC5 | -8619.0 |
BRCA2 | -8433.0 |
RBBP8 | -8270.0 |
RAD51 | -8226.0 |
KAT5 | -8198.0 |
RFC3 | -8030.0 |
RAD9B | -7770.5 |
BLM | -7501.0 |
RMI1 | -7389.5 |
DNA2 | -7266.0 |
TOP3A | -7020.5 |
RAD1 | -6683.5 |
RPA3 | -6328.0 |
EXO1 | -6078.0 |
RFC2 | -5672.0 |
HUS1 | -5490.0 |
RAD17 | -5393.5 |
XRCC2 | -4285.0 |
WRN | -4029.5 |
RPA1 | -3377.5 |
RAD9A | -3132.0 |
TOPBP1 | -3108.0 |
ATRIP | -2471.0 |
CHEK1 | -2304.0 |
RAD50 | -1967.0 |
NBN | -1658.0 |
RFC4 | -456.0 |
BARD1 | -363.0 |
BRIP1 | 349.0 |
Here is the session info with all the versions of packages used.
sessionInfo()
## R version 4.2.0 (2022-04-22)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 20.04.4 LTS
##
## Matrix products: default
## BLAS: /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.9.0
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.9.0
##
## locale:
## [1] LC_CTYPE=en_US.UTF-8 LC_NUMERIC=C
## [3] LC_TIME=en_US.UTF-8 LC_COLLATE=en_US.UTF-8
## [5] LC_MONETARY=en_US.UTF-8 LC_MESSAGES=en_US.UTF-8
## [7] LC_PAPER=en_US.UTF-8 LC_NAME=C
## [9] LC_ADDRESS=C LC_TELEPHONE=C
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C
##
## attached base packages:
## [1] parallel stats graphics grDevices utils datasets methods
## [8] base
##
## other attached packages:
## [1] pkgload_1.2.4 GGally_2.1.2 ggplot2_3.3.6 reshape2_1.4.4
## [5] beeswarm_0.4.0 gplots_3.1.3 gtools_3.9.2 tibble_3.1.7
## [9] echarts4r_0.4.3 mitch_1.4.1 eulerr_6.1.1 kableExtra_1.3.4
## [13] dplyr_1.0.9
##
## loaded via a namespace (and not attached):
## [1] Rcpp_1.0.8.3 svglite_2.1.0 rprojroot_2.0.3 assertthat_0.2.1
## [5] digest_0.6.29 utf8_1.2.2 mime_0.12 R6_2.5.1
## [9] plyr_1.8.7 evaluate_0.15 httr_1.4.3 highr_0.9
## [13] pillar_1.7.0 rlang_1.0.2 rstudioapi_0.13 jquerylib_0.1.4
## [17] rmarkdown_2.14 desc_1.4.1 webshot_0.5.3 stringr_1.4.0
## [21] htmlwidgets_1.5.4 munsell_0.5.0 shiny_1.7.1 compiler_4.2.0
## [25] httpuv_1.6.5 xfun_0.30 pkgconfig_2.0.3 systemfonts_1.0.4
## [29] htmltools_0.5.2 tidyselect_1.1.2 gridExtra_2.3 reshape_0.8.9
## [33] fansi_1.0.3 viridisLite_0.4.0 withr_2.5.0 crayon_1.5.1
## [37] later_1.3.0 brio_1.1.3 bitops_1.0-7 MASS_7.3-57
## [41] grid_4.2.0 jsonlite_1.8.0 xtable_1.8-4 gtable_0.3.0
## [45] lifecycle_1.0.1 DBI_1.1.2 magrittr_2.0.3 scales_1.2.0
## [49] KernSmooth_2.23-20 cli_3.3.0 stringi_1.7.6 promises_1.2.0.1
## [53] testthat_3.1.4 xml2_1.3.3 bslib_0.3.1 ellipsis_0.3.2
## [57] generics_0.1.2 vctrs_0.4.1 RColorBrewer_1.1-3 tools_4.2.0
## [61] glue_1.6.2 purrr_0.3.4 fastmap_1.1.0 yaml_2.3.5
## [65] colorspace_2.0-3 caTools_1.18.2 rvest_1.0.2 knitr_1.39
## [69] sass_0.4.1
END of report